{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:17:32Z","timestamp":1788887852862,"version":"build-2803163510"},"reference-count":265,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11886-024-02157-9","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T09:10:38Z","timestamp":1737191438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel Therapies for Right Ventricular Failure"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-8785","authenticated-orcid":false,"given":"Bibhuti B.","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"issue":"12","key":"2157_CR1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMra2207410","volume":"388","author":"BA Houston","year":"2023","unstructured":"Houston BA, Taichman DB, Brittain EL, Tedford RJ. Right Ventricular Failure. N Engl J Med. 2023;388(12):1111\u201325. https:\/\/doi.org\/10.1056\/NEJMra2207410.","journal-title":"N Engl J Med"},{"issue":"5","key":"2157_CR2","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.21037\/cdt-20-450","volume":"10","author":"JL Sanders","year":"2020","unstructured":"Sanders JL, Koestenberger M, Rosenkranz S, Maron BA. Right ventricular dysfunction and long-term risk of death. Cardiovascular Diagnosis and Therapy. 2020;10(5):1646\u201358. https:\/\/doi.org\/10.21037\/cdt-20-450.","journal-title":"Cardiovascular Diagnosis and Therapy"},{"issue":"17","key":"2157_CR3","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1161\/circulationaha.106.632208","volume":"114","author":"NF Voelkel","year":"2006","unstructured":"Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, et al. Right Ventricular Function and Failure. Circulation. 2006;114(17):1883\u201391. https:\/\/doi.org\/10.1161\/circulationaha.106.632208.","journal-title":"Circulation"},{"issue":"20","key":"2157_CR4","doi-asserted-by":"publisher","first-page":"e578","DOI":"10.1161\/CIR.0000000000000560FromNLMMedline","volume":"137","author":"MA Konstam","year":"2018","unstructured":"Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, Kociol RD, Lewis EF, Mehra MR, Pagani FD, et al. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2018;137(20):e578\u2013622. https:\/\/doi.org\/10.1161\/CIR.0000000000000560FromNLMMedline.","journal-title":"Circulation"},{"issue":"5","key":"2157_CR5","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.21037\/cdt-20-592FromNLMPubMed-not-MEDLINE","volume":"10","author":"A Klinke","year":"2020","unstructured":"Klinke A, Schubert T, Muller M, Legchenko E, Zelt JGE, Shimauchi T, Napp LC, Rothman AMK, Bonnet S, Stewart DJ, et al. Emerging therapies for right ventricular dysfunction and failure. Cardiovasc Diagn Ther. 2020;10(5):1735\u201367. https:\/\/doi.org\/10.21037\/cdt-20-592FromNLMPubMed-not-MEDLINE.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"10","key":"2157_CR6","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/circresaha.121.318241","volume":"128","author":"GD Lopaschuk","year":"2021","unstructured":"Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac Energy Metabolism in Heart Failure. Circ Res. 2021;128(10):1487\u2013513. https:\/\/doi.org\/10.1161\/circresaha.121.318241.","journal-title":"Circ Res"},{"issue":"5","key":"2157_CR7","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.21037\/cdt-20-404FromNLMPubMed-not-MEDLINE","volume":"10","author":"V Agrawal","year":"2020","unstructured":"Agrawal V, Lahm T, Hansmann G, Hemnes AR. Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose\/lipid metabolism. Cardiovasc Diagn Ther. 2020;10(5):1522\u201340. https:\/\/doi.org\/10.21037\/cdt-20-404FromNLMPubMed-not-MEDLINE.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"1","key":"2157_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40256-023-00613-5FromNLMMedline","volume":"24","author":"OA Nabeh","year":"2024","unstructured":"Nabeh OA, Saud AI, Amin B, Khedr AS, Amr A, Faoosa AM, Esmat E, Mahmoud YM, Hatem A, Mohamed M, et al. A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension. Am J Cardiovasc Drugs. 2024;24(1):39\u201354. https:\/\/doi.org\/10.1007\/s40256-023-00613-5FromNLMMedline.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"2157_CR9","doi-asserted-by":"publisher","first-page":"e002206","DOI":"10.1161\/CIRCHEARTFAILURE.115.002206FromNLMMedline","volume":"9","author":"HN Sabbah","year":"2016","unstructured":"Sabbah HN, Gupta RC, Kohli S, Wang M, Hachem S, Zhang K. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016;9(2):e002206. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002206FromNLMMedline.","journal-title":"Circ Heart Fail"},{"issue":"10","key":"2157_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00109-013-1064-7","volume":"91","author":"L Piao","year":"2013","unstructured":"Piao L, Fang Y-H, Parikh K, Ryan JJ, Toth PT, Archer SL. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med. 2013;91(10):1185\u201397. https:\/\/doi.org\/10.1007\/s00109-013-1064-7.","journal-title":"J Mol Med"},{"key":"2157_CR11","doi-asserted-by":"publisher","unstructured":"Dewachter L, Dewachter C. Inflammation in Right Ventricular Failure: Does It Matter? Frontiers in Physiology 2018;9. https:\/\/doi.org\/10.3389\/fphys.2018.01056.","DOI":"10.3389\/fphys.2018.01056"},{"issue":"5","key":"2157_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11897-022-00572-z","volume":"19","author":"MR Lippmann","year":"2022","unstructured":"Lippmann MR, Maron BA. The Right Ventricle: From Embryologic Development to RV Failure. Curr Heart Fail Rep. 2022;19(5):325\u201333. https:\/\/doi.org\/10.1007\/s11897-022-00572-z.","journal-title":"Curr Heart Fail Rep"},{"key":"2157_CR13","doi-asserted-by":"publisher","unstructured":"Sydykov A, Mamazhakypov A, Petrovic A, Kosanovic D, Sarybaev AS, Weissmann N Ghofrani HA, Schermuly RT. Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. Front Physiology 2018;9. https:\/\/doi.org\/10.3389\/fphys.2018.00609.","DOI":"10.3389\/fphys.2018.00609"},{"key":"2157_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.matbio.2018.01.010","volume":"68\u201369","author":"B Egemnazarov","year":"2018","unstructured":"Egemnazarov B, Crnkovic S, Nagy BM, Olschewski H, Kwapiszewska G. Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions. Matrix Biol. 2018;68\u201369:507\u201321. https:\/\/doi.org\/10.1016\/j.matbio.2018.01.010.","journal-title":"Matrix Biol"},{"issue":"4","key":"2157_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/138161282104141204124129","volume":"21","author":"A Roe","year":"2014","unstructured":"Roe A, Frisk M, Louch W. Targeting Cardiomyocyte Ca2+ Homeostasis in Heart Failure. Curr Pharm Des. 2014;21(4):431\u201348. https:\/\/doi.org\/10.2174\/138161282104141204124129.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"2157_CR16","doi-asserted-by":"publisher","first-page":"L443","DOI":"10.1152\/ajplung.00374.2017","volume":"314","author":"AL Frump","year":"2018","unstructured":"Frump AL, Bonnet S, De Jesus Perez VA, Lahm T. Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. Am J Physiology-Lung Cellular Mol Physiology. 2018;314(3):L443\u201360. https:\/\/doi.org\/10.1152\/ajplung.00374.2017.","journal-title":"Am J Physiology-Lung Cellular Mol Physiology"},{"issue":"10","key":"2157_CR17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cardfail.2013.08.004","volume":"19","author":"M DuPont","year":"2013","unstructured":"DuPont M, Tang WHW. Right Ventricular Afterload and the Role of Nitric Oxide Metabolism in Left-Sided Heart Failure. J Cardiac Fail. 2013;19(10):712\u201321. https:\/\/doi.org\/10.1016\/j.cardfail.2013.08.004.","journal-title":"J Cardiac Fail"},{"key":"2157_CR18","doi-asserted-by":"publisher","unstructured":"Park JF, Clark VR, Banerjee S, Hong J, Razee A. Williams, T.; Fishbein, G.; Saddic, L.; Umar, S. Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension. Circulation: Heart Failure 2021;14(2). https:\/\/doi.org\/10.1161\/circheartfailure.120.007058.","DOI":"10.1161\/circheartfailure.120.007058"},{"issue":"6","key":"2157_CR19","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1292\/jvms.17-0053","volume":"79","author":"K Imoto","year":"2017","unstructured":"Imoto K, Okada M, Yamawaki H. Expression profile of matricellular proteins in hypertrophied right ventricle of monocrotaline-induced pulmonary hypertensive rats. J Vet Med Sci. 2017;79(6):1096\u2013102. https:\/\/doi.org\/10.1292\/jvms.17-0053.","journal-title":"J Vet Med Sci"},{"issue":"7","key":"2157_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41569-021-00646-wFromNLMMedline","volume":"19","author":"NG Frangogiannis","year":"2022","unstructured":"Frangogiannis NG. Transforming growth factor-beta in myocardial disease. Nat Rev Cardiol. 2022;19(7):435\u201355. https:\/\/doi.org\/10.1038\/s41569-021-00646-wFromNLMMedline.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"2157_CR21","doi-asserted-by":"publisher","first-page":"H2007","DOI":"10.1152\/ajpheart.00089.2009","volume":"296","author":"I Falc\u00e3o-Pires","year":"2009","unstructured":"Falc\u00e3o-Pires I, Gon\u00e7alves N, Henriques-Coelho T, Moreira-Gon\u00e7alves D, Roncon-Albuquerque R, Leite-Moreira AF. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiology-Heart Circulatory Physiology. 2009;296(6):H2007\u201314. https:\/\/doi.org\/10.1152\/ajpheart.00089.2009.","journal-title":"Am J Physiology-Heart Circulatory Physiology"},{"issue":"3","key":"2157_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1378\/chest.08-1758","volume":"135","author":"SM Kawut","year":"2009","unstructured":"Kawut SM, Al-Naamani N, Agerstrand C, Berman Rosenzweig E, Rowan C, Barst RJ, Bergmann S, Horn EM. Determinants of Right Ventricular Ejection Fraction in Pulmonary Arterial Hypertension. Chest. 2009;135(3):752\u20139. https:\/\/doi.org\/10.1378\/chest.08-1758.","journal-title":"Chest"},{"issue":"2","key":"2157_CR23","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/ehf2.14233","volume":"10","author":"ZA Rako","year":"2023","unstructured":"Rako ZA, Kremer N, Yogeswaran A, Richter MJ, Tello K. Adaptive versus maladaptive right ventricular remodeling. ESC Heart Failure. 2023;10(2):762\u201375. https:\/\/doi.org\/10.1002\/ehf2.14233.","journal-title":"ESC Heart Failure"},{"key":"2157_CR24","doi-asserted-by":"publisher","unstructured":"Hsu S, Simpson CE, Houston BA, Wand A, Sato T, Kolb TM, Mathai SC,Kass DA, Hassoun PM, Damico RL et al. Multi\u2010Beat Right Ventricular\u2010Arterial Coupling Predicts Clinical Worsening in Pulmonary Arterial Hypertension. J Am Heart Association 2020;9(10). https:\/\/doi.org\/10.1161\/jaha.119.016031.","DOI":"10.1161\/jaha.119.016031"},{"key":"2157_CR25","doi-asserted-by":"publisher","unstructured":"Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani HA, Naeije R, Roller F, Mohajerani E, Seeger W, Herberg U et al. Validation of the Tricuspid Annular Plane Systolic Excursion\/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circulation: Cardiovascular Imaging 2019;12(9). https:\/\/doi.org\/10.1161\/circimaging.119.009047.","DOI":"10.1161\/circimaging.119.009047"},{"issue":"1","key":"2157_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10741-023-10341-2","volume":"29","author":"V Anastasiou","year":"2023","unstructured":"Anastasiou V, Papazoglou AS, Moysidis DV, Daios S, Barmpagiannos K, Gossios T, Efthimiadis GK, Karamitsos T, Ziakas A, Kamperidis V. The prognostic impact of right ventricular-pulmonary arterial coupling in heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2023;29(1):13\u201326. https:\/\/doi.org\/10.1007\/s10741-023-10341-2.","journal-title":"Heart Fail Rev"},{"issue":"5","key":"2157_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3760\/cma.j.cn121430-20210401-00482FromNLMMedline","volume":"34","author":"J Liu","year":"2022","unstructured":"Liu J, Han D, Wang T, Liu P, Zhao Y, Zuo X. Role of inflammation and apoptosis in right ventricular dysfunction induced by injurious mechanical ventilation in rats. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022;34(5):519\u201324. https:\/\/doi.org\/10.3760\/cma.j.cn121430-20210401-00482FromNLMMedline.","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"2157_CR28","doi-asserted-by":"publisher","first-page":"108389","DOI":"10.1016\/j.pharmthera.2023.108389FromNLMMedline","volume":"244","author":"FT Bekedam","year":"2023","unstructured":"Bekedam FT, Goumans MJ, Bogaard HJ, de Man FS, Llucia-Valldeperas A. Molecular mechanisms and targets of right ventricular fibrosis in pulmonary hypertension. Pharmacol Ther. 2023;244:108389. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108389FromNLMMedline.","journal-title":"Pharmacol Ther"},{"key":"2157_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijcard.2019.06.065","volume":"293","author":"S Andersen","year":"2019","unstructured":"Andersen S, Axelsen JB, Ringgaard S, Nyengaard JR, Hyldebrandt JA, Bogaard HJ, de Man FS, Nielsen-Kudsk JE, Andersen A. Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure. Int J Cardiol. 2019;293:203\u201310. https:\/\/doi.org\/10.1016\/j.ijcard.2019.06.065.","journal-title":"Int J Cardiol"},{"key":"2157_CR30","doi-asserted-by":"publisher","unstructured":"Okni\u0144ska M, Zajda K, Zambrowska Z, Grzanka M, Paterek A, Mackiewicz U, Szczylik C, Kurzyna M, Piekie\u0142ko-Witkowska A, Torbicki A et al. Role of Oxygen Starvation in Right Ventricular Decompensation and Failure in Pulmonary Arterial Hypertension. JACC: Heart Failure 2024;12 (2), 235\u2013247. https:\/\/doi.org\/10.1016\/j.jchf.2023.03.010.","DOI":"10.1016\/j.jchf.2023.03.010"},{"issue":"6","key":"2157_CR31","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s12350-020-02144-xFromNLMMedline","volume":"28","author":"A Ahmadi","year":"2021","unstructured":"Ahmadi A, Renaud JM, Promislow S, Burwash IG, Dwivedi G, Klein R, Zelt JGE, deKemp RA, Beanlands RS, Mielniczuk LM. Increased myocardial oxygen consumption rates are associated with maladaptive right ventricular remodeling and decreased event-free survival in heart failure patients. J Nucl Cardiol. 2021;28(6):2784\u201395. https:\/\/doi.org\/10.1007\/s12350-020-02144-xFromNLMMedline.","journal-title":"J Nucl Cardiol"},{"issue":"1\u20132","key":"2157_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11010-019-03652-2","volume":"464","author":"A Zimmer","year":"2020","unstructured":"Zimmer A, Teixeira RB, Bonetto JHP, Bahr AC, T\u00fcrck P, De Castro AL, Campos-Carraro C, Visioli F, Fernandes-Piedras TR, Casali KR, et al. Role of inflammation, oxidative stress, and autonomic nervous system activation during the development of right and left cardiac remodeling in experimental pulmonary arterial hypertension. Mol Cell Biochem. 2020;464(1\u20132):93\u2013109. https:\/\/doi.org\/10.1007\/s11010-019-03652-2.","journal-title":"Mol Cell Biochem"},{"key":"2157_CR33","doi-asserted-by":"publisher","unstructured":"Brittain EL, Niswender K, Agrawal V, Chen X, Fan R, Pugh ME, Rice TW, Robbins IM, Song H, Thompson C et al. Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension. J American Heart Association 2020;9(22). https:\/\/doi.org\/10.1161\/jaha.120.018349.","DOI":"10.1161\/jaha.120.018349"},{"issue":"5","key":"2157_CR34","doi-asserted-by":"publisher","first-page":"L435","DOI":"10.1152\/ajplung.00169.2015FromNLMMedline","volume":"309","author":"BB Graham","year":"2015","unstructured":"Graham BB, Kumar R, Mickael C, Sanders L, Gebreab L, Huber KM, Perez M, Smith-Jones P, Serkova NJ, Tuder RM. Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. Am J Physiol Lung Cell Mol Physiol. 2015;309(5):L435-440. https:\/\/doi.org\/10.1152\/ajplung.00169.2015FromNLMMedline.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"2157_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/circulationaha.118.035326","volume":"139","author":"S Andersen","year":"2019","unstructured":"Andersen S, Nielsen-Kudsk JE, Vonk Noordegraaf A, De Man FS. Right Ventricular Fibrosis. Circulation. 2019;139(2):269\u201385. https:\/\/doi.org\/10.1161\/circulationaha.118.035326.","journal-title":"Circulation"},{"key":"2157_CR36","doi-asserted-by":"publisher","unstructured":"Liu S, Wang Y, Lu S, Hu J, Zeng X, Liu W, Wang Y, Wang Z. Sacubitril\/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism. Life Sciences 2021;266. https:\/\/doi.org\/10.1016\/j.lfs.2020.118877.","DOI":"10.1016\/j.lfs.2020.118877"},{"key":"2157_CR37","doi-asserted-by":"publisher","unstructured":"Bezhaeva T, Karper J, Quax PHA, De Vries MR. The Intriguing Role of TLR Accessory Molecules in Cardiovascular Health and Disease. Frontiers in Cardiovascular Medicine 2022;9. https:\/\/doi.org\/10.3389\/fcvm.2022.820962.","DOI":"10.3389\/fcvm.2022.820962"},{"issue":"2","key":"2157_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/jcdd11020054","volume":"11","author":"A Mamazhakypov","year":"2024","unstructured":"Mamazhakypov A, Maripov A, Sarybaev AS, Schermuly RT, Sydykov A. Mast Cells in Cardiac Remodeling: Focus on the Right Ventricle. J Cardiovascular Dev Dis. 2024;11(2):54. https:\/\/doi.org\/10.3390\/jcdd11020054.","journal-title":"J Cardiovascular Dev Dis"},{"issue":"4","key":"2157_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/cvr\/cvx017","volume":"113","author":"J Ritterhoff","year":"2017","unstructured":"Ritterhoff J, Tian R. Metabolism in cardiomyopathy: every substrate matters. Cardiovasc Res. 2017;113(4):411\u201321. https:\/\/doi.org\/10.1093\/cvr\/cvx017.","journal-title":"Cardiovasc Res"},{"issue":"13","key":"2157_CR40","doi-asserted-by":"publisher","first-page":"11108","DOI":"10.3390\/ijms241311108","volume":"24","author":"M M\u00fcller","year":"2023","unstructured":"M\u00fcller M, Donhauser E, Maske T, Bischof C, Dumitrescu D, Rudolph V, Klinke A. Mitochondrial Integrity Is Critical in Right Heart Failure Development. Int J Mol Sci. 2023;24(13):11108. https:\/\/doi.org\/10.3390\/ijms241311108.","journal-title":"Int J Mol Sci"},{"key":"2157_CR41","doi-asserted-by":"publisher","unstructured":"Lu J, Qian S, Sun Z. Targeting histone deacetylase in cardiac diseases. Frontiers in Physiology 2024;15. https:\/\/doi.org\/10.3389\/fphys.2024.1405569.","DOI":"10.3389\/fphys.2024.1405569"},{"key":"2157_CR42","doi-asserted-by":"publisher","unstructured":"Alipour Symakani RS, Van Genuchten WJ, Zandbergen LM, Henry S, Taverne YJHJ, Merkus D, Helbing WA. Bartelds, B. The right ventricle in tetralogy of Fallot: adaptation to sequential loading. Frontiers in Pediatrics 2023;11. https:\/\/doi.org\/10.3389\/fped.2023.1098248.","DOI":"10.3389\/fped.2023.1098248"},{"issue":"6","key":"2157_CR43","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11897-022-00577-8","volume":"19","author":"MP N\u00e4gele","year":"2022","unstructured":"N\u00e4gele MP, Flammer AJ. Heart Failure After Right Ventricular Myocardial Infarction. Curr Heart Fail Rep. 2022;19(6):375\u201385. https:\/\/doi.org\/10.1007\/s11897-022-00577-8.","journal-title":"Curr Heart Fail Rep"},{"issue":"10","key":"2157_CR44","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/echo.15449","volume":"39","author":"M Maharlou","year":"2022","unstructured":"Maharlou M, Kaviani R, Rezaeian N, Amin A, Omidvar R, Farrashi M. Right ventricular peak systolic free wall longitudinal strain as a practical tool to detect right ventricular dysfunction in acute myocarditis. Echocardiography. 2022;39(10):1291\u20138. https:\/\/doi.org\/10.1111\/echo.15449.","journal-title":"Echocardiography"},{"issue":"3","key":"2157_CR45","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1053\/j.jvca.2018.07.048FromNLMMedline","volume":"33","author":"PC Ting","year":"2019","unstructured":"Ting PC, Wu VC, Liao CC, Chou AH, Tsai FC, Lin PJ, Chen CY, Chen SW. Preoperative Right Ventricular Dysfunction Indicates High Vasoactive Support Needed After Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019;33(3):686\u201393. https:\/\/doi.org\/10.1053\/j.jvca.2018.07.048FromNLMMedline.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"S5","key":"2157_CR46","doi-asserted-by":"publisher","first-page":"S674","DOI":"10.21037\/jtd.2017.10.75","volume":"10","author":"JJH Bunge","year":"2018","unstructured":"Bunge JJH, Caliskan K, Gommers D, Miranda DR. Right ventricular dysfunction during acute respiratory distress syndrome and veno-venous extracorporeal membrane oxygenation. J Thorac Dis. 2018;10(S5):S674\u201382. https:\/\/doi.org\/10.21037\/jtd.2017.10.75.","journal-title":"J Thorac Dis"},{"issue":"22","key":"2157_CR47","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1111\/bph.12829","volume":"171","author":"P Shukla","year":"2014","unstructured":"Shukla P, Rao GM, Pandey G, Sharma S, Mittapelly N, Shegokar R, Mishra PR. Therapeutic interventions in sepsis: current and anticipated pharmacological agents. Br J Pharmacol. 2014;171(22):5011\u201331. https:\/\/doi.org\/10.1111\/bph.12829.","journal-title":"Br J Pharmacol"},{"key":"2157_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ahj.2018.11.010FromNLMMedline","volume":"209","author":"DS Burstein","year":"2019","unstructured":"Burstein DS, Shamszad P, Dai D, Almond CS, Price JF, Lin KY, O\u2019Connor MJ, Shaddy RE, Mascio CE, Rossano JW. Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults. Am Heart J. 2019;209:9\u201319. https:\/\/doi.org\/10.1016\/j.ahj.2018.11.010FromNLMMedline.","journal-title":"Am Heart J"},{"key":"2157_CR49","unstructured":"Loire R, Tabib A. [Arrhythmogenic right ventricular dysplasia and Uhl disease. Anatomic study of 100 cases after sudden death]. Ann Pathol 1998;18(3):165\u2013171. From NLM Medline."},{"key":"2157_CR50","doi-asserted-by":"publisher","unstructured":"Kaveevorayan P, Tokavanich N, Kittipibul V, Lertsuttimetta T, Singhatanadgige S, Ongcharit P, Sinphurmsukskul S, Ariyachaipanich A, Siwamogsatham S, Thammanatsakul K et al. Primary isolated right ventricular failure after heart transplantation: prevalence, right ventricular characteristics, and outcomes. Scientific Reports 2023;13(1). https:\/\/doi.org\/10.1038\/s41598-023-27482-x.","DOI":"10.1038\/s41598-023-27482-x"},{"issue":"2","key":"2157_CR51","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.bpa.2012.03.006FromNLMMedline","volume":"26","author":"M Meineri","year":"2012","unstructured":"Meineri M, Van Rensburg AE, Vegas A. Right ventricular failure after LVAD implantation: prevention and treatment. Best Pract Res Clin Anesthesiol. 2012;26(2):217\u201329. https:\/\/doi.org\/10.1016\/j.bpa.2012.03.006FromNLMMedline.","journal-title":"Best Pract Res Clin Anesthesiol"},{"issue":"9","key":"2157_CR52","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.healun.2015.06.015","volume":"34","author":"BC Lampert","year":"2015","unstructured":"Lampert BC, Teuteberg JJ. Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant. 2015;34(9):1123\u201330. https:\/\/doi.org\/10.1016\/j.healun.2015.06.015.","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"2157_CR53","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.21037\/jtd-20-2228","volume":"13","author":"V Lo Coco","year":"2021","unstructured":"Lo Coco V, De Piero ME, Massimi G, Chiarini G, Raffa GM, Kowalewski M, Maessen J, Lorusso R. Right ventricular failure after left ventricular assist device implantation: a review of the literature. J Thorac Dis. 2021;13(2):1256\u201369. https:\/\/doi.org\/10.21037\/jtd-20-2228.","journal-title":"J Thorac Dis"},{"issue":"3","key":"2157_CR54","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cjca.2014.12.006FromNLMMedline","volume":"31","author":"L Grosman-Rimon","year":"2015","unstructured":"Grosman-Rimon L, Jacobs I, Tumiati LC, McDonald MA, Bar-Ziv SP, Fuks A, Kawajiri H, Lazarte J, Ghashghai A, Shogilev DJ, et al. Longitudinal assessment of inflammation in recipients of continuous-flow left ventricular assist devices. Can J Cardiol. 2015;31(3):348\u201356. https:\/\/doi.org\/10.1016\/j.cjca.2014.12.006FromNLMMedline.","journal-title":"Can J Cardiol"},{"issue":"1","key":"2157_CR55","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/ijms25010288","volume":"25","author":"A Galeone","year":"2023","unstructured":"Galeone A, Buccoliero C, Barile B, Nicchia GP, Onorati F, Luciani GB, Brunetti G. Cellular and Molecular Mechanisms Activated by a Left Ventricular Assist Device. Int J Mol Sci. 2023;25(1):288. https:\/\/doi.org\/10.3390\/ijms25010288.","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2157_CR56","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/nejmoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/nejmoa1504720.","journal-title":"N Engl J Med"},{"issue":"4","key":"2157_CR57","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/cvr\/cvab123FromNLMMedline","volume":"118","author":"E Torre","year":"2022","unstructured":"Torre E, Arici M, Lodrini AM, Ferrandi M, Barassi P, Hsu SC, Chang GJ, Boz E, Sala E, Vagni S, et al. SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy. Cardiovasc Res. 2022;118(4):1020\u201332. https:\/\/doi.org\/10.1093\/cvr\/cvab123FromNLMMedline.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"2157_CR58","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","volume":"15","author":"E Bertero","year":"2018","unstructured":"Bertero E, Maack C. Metabolic remodeling in heart failure. Nat Rev Cardiol. 2018;15(8):457\u201370. https:\/\/doi.org\/10.1038\/s41569-018-0044-6.","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"2157_CR59","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1172\/jci120849","volume":"128","author":"B Zhou","year":"2018","unstructured":"Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Investig. 2018;128(9):3716\u201326. https:\/\/doi.org\/10.1172\/jci120849.","journal-title":"J Clin Investig"},{"issue":"6","key":"2157_CR60","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/cells10061559","volume":"10","author":"T Hautbergue","year":"2021","unstructured":"Hautbergue T, Antigny F, Bo\u00ebt A, Haddad F, Masson B, Lambert M, Delaporte A, Menager J-B, Savale L, Pavec JL, et al. Right Ventricle Remodeling Metabolic Signature in Experimental Pulmonary Hypertension Models of Chronic Hypoxia and Monocrotaline Exposure. Cells. 2021;10(6):1559. https:\/\/doi.org\/10.3390\/cells10061559.","journal-title":"Cells"},{"key":"2157_CR61","doi-asserted-by":"publisher","unstructured":"B\u00f8gh N, Hansen ESS, Omann C, Lindhardt J, Nielsen PM, Stephenson RS, Laustsen C, Hjortdal VE, Agger P. Increasing carbohydrate oxidation improves contractile reserves and prevents hypertrophy in porcine right heart failure. Scientific Reports 2020;10(1). https:\/\/doi.org\/10.1038\/s41598-020-65098-7.","DOI":"10.1038\/s41598-020-65098-7"},{"issue":"1","key":"2157_CR62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00109-011-0804-9","volume":"90","author":"Y-H Fang","year":"2012","unstructured":"Fang Y-H, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, Archer SL. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle\u2019s cycle. J Mol Med. 2012;90(1):31\u201343. https:\/\/doi.org\/10.1007\/s00109-011-0804-9.","journal-title":"J Mol Med"},{"issue":"1","key":"2157_CR63","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/2045-8932.109960","volume":"3","author":"SL Archer","year":"2013","unstructured":"Archer SL, Fang YH, Ryan JJ, Piao L. Metabolism and Bioenergetics in the Right Ventricle and Pulmonary Vasculature in Pulmonary Hypertension. Pulmonary Circulation. 2013;3(1):144\u201352. https:\/\/doi.org\/10.4103\/2045-8932.109960.","journal-title":"Pulmonary Circulation"},{"issue":"5","key":"2157_CR64","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1172\/jci32503","volume":"118","author":"G Hansmann","year":"2008","unstructured":"Hansmann G, De Jesus Perez VA, Alastalo T-P, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, et al. An antiproliferative BMP-2\/PPAR\u03b3\/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Investig. 2008;118(5):1846\u201357. https:\/\/doi.org\/10.1172\/jci32503.","journal-title":"J Clin Investig"},{"issue":"2","key":"2157_CR65","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1165\/rcmb.2019-0226PSFromNLMMedline","volume":"62","author":"G Hansmann","year":"2020","unstructured":"Hansmann G, Calvier L, Risbano MG, Chan SY. Activation of the Metabolic Master Regulator PPARgamma: A Potential PIOneering Therapy for Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol. 2020;62(2):143\u201356. https:\/\/doi.org\/10.1165\/rcmb.2019-0226PSFromNLMMedline.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"2157_CR66","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1476-5381.2009.00445.x","volume":"158","author":"C Agard","year":"2009","unstructured":"Agard C, Rolli-Derkinderen M, Dumas-De-La-Roque E, Rio M, Sagan C, Savineau J, Loirand G, Pacaud P. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J Pharmacol. 2009;158(5):1285\u201394. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00445.x.","journal-title":"Br J Pharmacol"},{"issue":"18","key":"2157_CR67","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1177\/15353702231191178FromNLMMedline","volume":"248","author":"Y Wu","year":"2023","unstructured":"Wu Y. Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose by upregulating AMPK activity. Exp Biol Med (Maywood). 2023;248(18):1556\u201365. https:\/\/doi.org\/10.1177\/15353702231191178FromNLMMedline.","journal-title":"Exp Biol Med (Maywood)"},{"key":"2157_CR68","doi-asserted-by":"publisher","unstructured":"Mussbacher, M.; Derler, M.; Bas\u00edlio, J.; Schmid, J. A. NF-\u03baB in monocytes and macrophages \u2013 an inflammatory master regulator in multitalented immune cells. Frontiers in Immunology 2023, 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1134661.","DOI":"10.3389\/fimmu.2023.1134661"},{"key":"2157_CR69","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M. Ting JP The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477\u201389. https:\/\/doi.org\/10.1038\/s41577-019-0165-0.","journal-title":"Nat Rev Immunol"},{"issue":"16","key":"2157_CR70","doi-asserted-by":"publisher","first-page":"8297","DOI":"10.3390\/ijerph18168297","volume":"18","author":"A Mamazhakypov","year":"2021","unstructured":"Mamazhakypov A, Sommer N, Assmus B, Tello K, Schermuly RT, Kosanovic D, Sarybaev AS, Weissmann N, Pak O. Novel Therapeutic Targets for the Treatment of Right Ventricular Remodeling: Insights from the Pulmonary Artery Banding Model. Int J Environ Res Public Health. 2021;18(16):8297. https:\/\/doi.org\/10.3390\/ijerph18168297.","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"2157_CR71","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/cvr\/cvx159","volume":"113","author":"X-Q Sun","year":"2017","unstructured":"Sun X-Q, Abbate A, Bogaard H-J. Role of cardiac inflammation in right ventricular failure. Cardiovasc Res. 2017;113(12):1441\u201352. https:\/\/doi.org\/10.1093\/cvr\/cvx159.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"2157_CR72","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1165\/rcmb.2011-0396CFromNLMMedline","volume":"49","author":"S Eba","year":"2013","unstructured":"Eba S, Hoshikawa Y, Moriguchi T, Mitsuishi Y, Satoh H, Ishida K, Watanabe T, Shimizu T, Shimokawa H, Okada Y, et al. The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice. Am J Respir Cell Mol Biol. 2013;49(2):324\u201333. https:\/\/doi.org\/10.1165\/rcmb.2011-0396CFromNLMMedline.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"20","key":"2157_CR73","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1161\/circulationaha.109.883843","volume":"120","author":"HJ Bogaard","year":"2009","unstructured":"Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic Pulmonary Artery Pressure Elevation Is Insufficient to Explain Right Heart Failure. Circulation. 2009;120(20):1951\u201360. https:\/\/doi.org\/10.1161\/circulationaha.109.883843.","journal-title":"Circulation"},{"issue":"13","key":"2157_CR74","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.3390\/ijms21134777","volume":"21","author":"F He","year":"2020","unstructured":"He F, Ru X, Wen T. NRF2, a Transcription Factor for Stress Response and Beyond. Int J Mol Sci. 2020;21(13):4777. https:\/\/doi.org\/10.3390\/ijms21134777.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2157_CR75","doi-asserted-by":"publisher","first-page":"e2005924","DOI":"10.1371\/journal.pbio.2005924","volume":"16","author":"J Boehme","year":"2018","unstructured":"Boehme J, Le Moan N, Kameny RJ, Loucks A, Johengen MJ, Lesneski AL, Gong W, Goudy BD, Davis T, Tanaka K, et al. Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. PLoS Biol. 2018;16(10):e2005924. https:\/\/doi.org\/10.1371\/journal.pbio.2005924.","journal-title":"PLoS Biol"},{"issue":"18","key":"2157_CR76","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.jacc.2010.05.046FromNLMMedline","volume":"56","author":"T Lahm","year":"2010","unstructured":"Lahm T, McCaslin CA, Wozniak TC, Ghumman W, Fadl YY, Obeidat OS, Schwab K, Meldrum DR. Medical and surgical treatment of acute right ventricular failure. J Am Coll Cardiol. 2010;56(18):1435\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.046FromNLMMedline.","journal-title":"J Am Coll Cardiol"},{"key":"2157_CR77","doi-asserted-by":"publisher","unstructured":"Shi Z, Gao F, Liu W, He X. Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis. Frontiers in Cardiovascular Medicine 2022;9. https:\/\/doi.org\/10.3389\/fcvm.2022.869272.","DOI":"10.3389\/fcvm.2022.869272"},{"issue":"6","key":"2157_CR78","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.jtcvs.2019.06.001","volume":"158","author":"HM Burkhart","year":"2019","unstructured":"Burkhart HM, Qureshi MY, Rossano JW, Cantero Peral S, O\u2019Leary PW, Hathcock M, Kremers W, Nelson TJ, Breuer A, Cavanaugh K, et al. Autologous stem cell therapy for hypoplastic left heart syndrome: Safety and feasibility of intraoperative intramyocardial injections. J Thorac Cardiovasc Surg. 2019;158(6):1614\u201323. https:\/\/doi.org\/10.1016\/j.jtcvs.2019.06.001.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"7","key":"2157_CR79","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00246-022-02872-6","volume":"43","author":"S Kaushal","year":"2022","unstructured":"Kaushal S, Hare JM, Shah AM, Pietris NP, Bettencourt JL, Piller LB, Khan A, Snyder A, Boyd RM, Abdullah M, et al. Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study). Pediatr Cardiol. 2022;43(7):1481\u201393. https:\/\/doi.org\/10.1007\/s00246-022-02872-6.","journal-title":"Pediatr Cardiol"},{"issue":"12","key":"2157_CR80","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jacbts.2020.07.011FromNLMPubMed-not-MEDLINE","volume":"5","author":"SZ Prisco","year":"2020","unstructured":"Prisco SZ, Thenappan T, Prins KW. Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. JACC Basic Transl Sci. 2020;5(12):1244\u201360. https:\/\/doi.org\/10.1016\/j.jacbts.2020.07.011FromNLMPubMed-not-MEDLINE.","journal-title":"JACC Basic Transl Sci"},{"key":"2157_CR81","doi-asserted-by":"publisher","unstructured":"Lin Y, Zhang H, Zhao S, Chen L, Li J, Wang X, Tian W. The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis. Frontiers in Cardiovascular Medicine 2022;9. https:\/\/doi.org\/10.3389\/fcvm.2022.882089.","DOI":"10.3389\/fcvm.2022.882089"},{"key":"2157_CR82","doi-asserted-by":"publisher","unstructured":"Tsai M-L, Lin Y, Lin M-S, Tsai T-H, Yang N-I, Wang C-Y, Hsieh IC, Hung M-J, Chen T-H. Comparing angiotensin receptor\u2013neprilysin inhibitors with sodium\u2013glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus. Diabetology & Metabolic Syndrome 2023;15 (1). https:\/\/doi.org\/10.1186\/s13098-023-01081-2.","DOI":"10.1186\/s13098-023-01081-2"},{"issue":"7","key":"2157_CR83","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/medicina60071112","volume":"60","author":"BB Das","year":"2024","unstructured":"Das BB. Unlocking the Potential: Angiotensin Receptor Neprilysin and Sodium Glucose Co-Transporter 2 Inhibitors for Right Ventricle Dysfunction in Heart Failure. Medicina. 2024;60(7):1112. https:\/\/doi.org\/10.3390\/medicina60071112.","journal-title":"Medicina"},{"issue":"4","key":"2157_CR84","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors. J Am Coll Cardiol. 2020;75(4):422\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2157_CR85","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732FromNLMMedline","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling\/Autophagy Hypothesis. Circulation. 2022;146(18):1383\u2013405. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061732FromNLMMedline.","journal-title":"Circulation"},{"key":"2157_CR86","doi-asserted-by":"publisher","unstructured":"Giannattasio S, Citarella A, Trocchianesi S, Filardi T, Morano S, Lenzi A, Ferretti E, Crescioli C. Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes. Frontiers in Molecular Biosciences 2022;9. https:\/\/doi.org\/10.3389\/fmolb.2022.879522.","DOI":"10.3389\/fmolb.2022.879522"},{"issue":"4","key":"2157_CR87","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/jdi.13255","volume":"11","author":"R Sano","year":"2020","unstructured":"Sano R, Shinozaki Y, Ohta T. Sodium\u2013glucose cotransporters: Functional properties and pharmaceutical potential. Journal of Diabetes Investigation. 2020;11(4):770\u201382. https:\/\/doi.org\/10.1111\/jdi.13255.","journal-title":"Journal of Diabetes Investigation"},{"key":"2157_CR88","doi-asserted-by":"publisher","unstructured":"Benes J, Kotrc M, Wohlfahrt P, Kroupova K, Tupy M, Kautzner J, Melenovsky V. Right ventricular global dysfunction score: a new concept of right ventricular function assessment in patients with heart failure with reduced ejection fraction (HFrEF). Front Cardiovascular Med 2023; 10. https:\/\/doi.org\/10.3389\/fcvm.2023.1194174.","DOI":"10.3389\/fcvm.2023.1194174"},{"key":"2157_CR89","doi-asserted-by":"publisher","unstructured":"Iborra-Egea O, Santiago-Vacas E, Yurista SR, Lup\u00f3n J, Packer M, Heymans S, Zannad F, Butler J, Pascual-Figal D, Lax A et al. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart\u00a0Failure With Reduced Ejection Fraction With\u00a0or\u00a0Without Diabetes. JACC: Basic to Translational Science 2019;4 (7):831\u2013840. https:\/\/doi.org\/10.1016\/j.jacbts.2019.07.010.","DOI":"10.1016\/j.jacbts.2019.07.010"},{"issue":"1","key":"2157_CR90","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/FJC.0000000000001380FromNLMMedline","volume":"81","author":"Y Xie","year":"2023","unstructured":"Xie Y, Wei Y, Li D, Pu J, Ding H, Zhang X. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. J Cardiovasc Pharmacol. 2023;81(1):4\u201314. https:\/\/doi.org\/10.1097\/FJC.0000000000001380FromNLMMedline.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"2157_CR91","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3390\/cells9092134","volume":"9","author":"A Bellis","year":"2020","unstructured":"Bellis A, Mauro C, Barbato E, Di Gioia G, Sorriento D, Trimarco B, Morisco C. The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction. Cells. 2020;9(9):2134. https:\/\/doi.org\/10.3390\/cells9092134.","journal-title":"Cells"},{"key":"2157_CR92","doi-asserted-by":"publisher","unstructured":"Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V et al. Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM\u2010HF trial. European J Heart Failure 2016;18(10):1228\u20131234. https:\/\/doi.org\/10.1002\/ejhf.580.","DOI":"10.1002\/ejhf.580"},{"key":"2157_CR93","doi-asserted-by":"publisher","unstructured":"Hechter SJ, Fredriksen PM, Liu P, Veldtman G, Merchant N, Freeman M, Therrien J, Benson L, Siu S, Webb G. Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol 2001;87(5):660\u2013663, A611. https:\/\/doi.org\/10.1016\/s0002-9149(00)01452-1 From NLM Medline.","DOI":"10.1016\/s0002-9149(00)01452-1"},{"issue":"1","key":"2157_CR94","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijcard.2010.08.068FromNLMMedline","volume":"154","author":"O Tutarel","year":"2012","unstructured":"Tutarel O, Meyer GP, Bertram H, Wessel A, Schieffer B, Westhoff-Bleck M. Safety and efficiency of chronic ACE inhibition in symptomatic heart failure patients with a systemic right ventricle. Int J Cardiol. 2012;154(1):14\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2010.08.068FromNLMMedline.","journal-title":"Int J Cardiol"},{"issue":"19","key":"2157_CR95","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1001\/jama.2021.18463FromNLMMedline","volume":"326","author":"B Pieske","year":"2021","unstructured":"Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR, Investigators P, et al. Effect of Sacubitril\/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021;326(19):1919\u201329. https:\/\/doi.org\/10.1001\/jama.2021.18463FromNLMMedline.","journal-title":"JAMA"},{"key":"2157_CR96","doi-asserted-by":"publisher","unstructured":"Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Pi\u00f1a IL, Rocha RA, Shah AM et al. Association of Change in N-Terminal Pro\u2013B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. Jama 2019:322(11). https:\/\/doi.org\/10.1001\/jama.2019.12821.","DOI":"10.1001\/jama.2019.12821"},{"issue":"1","key":"2157_CR97","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748FromNLMMedline","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013748FromNLMMedline.","journal-title":"Circulation"},{"key":"2157_CR98","doi-asserted-by":"publisher","unstructured":"Sharifi Kia D, Benza E, Bachman TN, Tushak C, Kim K, Simon MA. Angiotensin Receptor\u2010Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension. J Am Heart Association 2020;9(13). https:\/\/doi.org\/10.1161\/jaha.119.015708.","DOI":"10.1161\/jaha.119.015708"},{"issue":"10","key":"2157_CR99","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/clc.24085","volume":"46","author":"X Mo","year":"2023","unstructured":"Mo X, Lu P, Yang X. Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta-analysis. Clin Cardiol. 2023;46(10):1137\u201345. https:\/\/doi.org\/10.1002\/clc.24085.","journal-title":"Clin Cardiol"},{"key":"2157_CR100","doi-asserted-by":"publisher","unstructured":"Bryan NS. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci 2009;(14). https:\/\/doi.org\/10.2741\/3228.","DOI":"10.2741\/3228"},{"issue":"23","key":"2157_CR101","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/eurheartj\/ehl337","volume":"27","author":"V Mitrovic","year":"2006","unstructured":"Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Luss H, et al. Hemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27(23):2823\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehl337.","journal-title":"Eur Heart J"},{"issue":"1","key":"2157_CR102","doi-asserted-by":"publisher","first-page":"H8","DOI":"10.1152\/ajpheart.01147.2003","volume":"287","author":"WJ Paulus","year":"2004","unstructured":"Paulus WJ, Bronzwaer JGF. Nitric oxide\u2019s role in the heart: control of beating or breathing? Am J Physiology-Heart and Circulatory Physiology. 2004;287(1):H8\u201313. https:\/\/doi.org\/10.1152\/ajpheart.01147.2003.","journal-title":"Am J Physiology-Heart and Circulatory Physiology"},{"issue":"3","key":"2157_CR103","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/01.Cir.102.3.351","volume":"102","author":"RM Varin","year":"2000","unstructured":"Varin RM, Mulder P, Tamion F, Richard V, Henry J-P, Lallemand FO, Lerebours G, Thuillez C. Improvement of Endothelial Function by Chronic Angiotensin-Converting Enzyme Inhibition in Heart Failure. Circulation. 2000;102(3):351\u20136. https:\/\/doi.org\/10.1161\/01.Cir.102.3.351.","journal-title":"Circulation"},{"issue":"5","key":"2157_CR104","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1161\/01.Cir.0000055737.15443.F8","volume":"107","author":"G Boerrigter","year":"2003","unstructured":"Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch J-P, Burnett JC. Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41\u20132272 in Experimental Congestive Heart Failure. Circulation. 2003;107(5):686\u20139. https:\/\/doi.org\/10.1161\/01.Cir.0000055737.15443.F8.","journal-title":"Circulation"},{"issue":"4","key":"2157_CR105","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1164\/rccm.201806-1160st","volume":"198","author":"T Lahm","year":"2018","unstructured":"Lahm T, Douglas IS, Archer SL, Bogaard HJ, Chesler NC, Haddad F, Hemnes AR, Kawut SM, Kline JA, Kolb TM, et al. Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. Am J Respiratory Critical Care Med. 2018;198(4):e15\u201343. https:\/\/doi.org\/10.1164\/rccm.201806-1160st.","journal-title":"Am J Respiratory Critical Care Med"},{"issue":"1","key":"2157_CR106","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/circresaha.113.301141","volume":"115","author":"M Rabinovitch","year":"2014","unstructured":"Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. Circ Res. 2014;115(1):165\u201375. https:\/\/doi.org\/10.1161\/circresaha.113.301141.","journal-title":"Circ Res"},{"issue":"4","key":"2157_CR107","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047FromNLMMedline","volume":"68","author":"CF Opitz","year":"2016","unstructured":"Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, Scelsi L, D\u2019Alto M, Olsson KM, Ulrich S, et al. Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. J Am Coll Cardiol. 2016;68(4):368\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2016.05.047FromNLMMedline.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2157_CR108","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1161\/circulationaha.115.020696","volume":"133","author":"CE Van Der Bruggen","year":"2016","unstructured":"Van Der Bruggen CE, Happ\u00e9 CM, Dorfm\u00fcller P, Trip P, Spruijt OA, Rol N, Hoevenaars FP, Houweling AC, Girerd B, Marcus JT, et al. Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension. Circulation. 2016;133(18):1747\u201360. https:\/\/doi.org\/10.1161\/circulationaha.115.020696.","journal-title":"Circulation"},{"issue":"6","key":"2157_CR109","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1183\/09031936.00160712","volume":"41","author":"A Vonk-Noordegraaf","year":"2013","unstructured":"Vonk-Noordegraaf A, Westerhof N. Describing right ventricular function. Eur Respir J. 2013;41(6):1419\u201323. https:\/\/doi.org\/10.1183\/09031936.00160712.","journal-title":"Eur Respir J"},{"issue":"10","key":"2157_CR110","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1161\/circulationaha.115.016382","volume":"132","author":"F Potus","year":"2015","unstructured":"Potus F, Ruffenach G, Dahou A, Thebault C, Breuils-Bonnet S, Tremblay \u00c8, Nadeau V, Paradis R, Graydon C, Wong R, et al. Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. Circulation. 2015;132(10):932\u201343. https:\/\/doi.org\/10.1161\/circulationaha.115.016382.","journal-title":"Circulation"},{"key":"2157_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01064-4","author":"H-A Ghofrani","year":"2024","unstructured":"Ghofrani H-A, Gomberg-Maitland M, Zhao L, Grimminger F. Mechanisms and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2024. https:\/\/doi.org\/10.1038\/s41569-024-01064-4.","journal-title":"Nat Rev Cardiol"},{"issue":"20","key":"2157_CR112","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/nejmoa050010","volume":"353","author":"N Gali\u00e8","year":"2005","unstructured":"Gali\u00e8 N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med. 2005;353(20):2148\u201357. https:\/\/doi.org\/10.1056\/nejmoa050010.","journal-title":"N Engl J Med"},{"issue":"26","key":"2157_CR113","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/nejmoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Gali\u00e8 N, Ghofrani H-A, Hoeper MM, Lang IM, Preiss R, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(26):2522\u201333. https:\/\/doi.org\/10.1056\/nejmoa1503184.","journal-title":"N Engl J Med"},{"issue":"22","key":"2157_CR114","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/circulationaha.108.839274","volume":"119","author":"N Gali\u00e8","year":"2009","unstructured":"Gali\u00e8 N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, et al. Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation. 2009;119(22):2894\u2013903. https:\/\/doi.org\/10.1161\/circulationaha.108.839274.","journal-title":"Circulation"},{"issue":"8","key":"2157_CR115","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.clinthera.2019.05.006FromNLMMedline","volume":"41","author":"HJ Chang","year":"2019","unstructured":"Chang HJ, Song S, Chang SA, Kim HK, Jung HO, Choi JH, Lee JS, Kim KH, Jeong JO, Lee JH, et al. Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind. Phase IIb Clinical Trial Clin Ther. 2019;41(8):1499\u2013507. https:\/\/doi.org\/10.1016\/j.clinthera.2019.05.006FromNLMMedline.","journal-title":"Phase IIb Clinical Trial Clin Ther"},{"issue":"4","key":"2157_CR116","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1530\/eje-15-1100","volume":"174","author":"D Santi","year":"2016","unstructured":"Santi D, Granata ARM, Guidi A, Pignatti E, Trenti T, Roli L, Bozic R, Zaza S, Pacchioni C, Romano S, et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. Eur J Endocrinol. 2016;174(4):513\u201322. https:\/\/doi.org\/10.1530\/eje-15-1100.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2157_CR117","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/iju.14785","volume":"29","author":"M Kumar","year":"2022","unstructured":"Kumar M, Pathade AD, Gupta SV, Goyal S, Rath D, Thakre M, Sanmukhani J, Mittal R. Efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction: A randomized, double blind, multicenter clinical trial. Int J Urol. 2022;29(4):351\u20139. https:\/\/doi.org\/10.1111\/iju.14785.","journal-title":"Int J Urol"},{"issue":"38","key":"2157_CR118","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237.","journal-title":"Eur Heart J"},{"issue":"5","key":"2157_CR119","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/nejm199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. N Engl J Med. 1996;334(5):296\u2013301. https:\/\/doi.org\/10.1056\/nejm199602013340504.","journal-title":"N Engl J Med"},{"issue":"6","key":"2157_CR120","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079FromNLMMedline","volume":"165","author":"G Simonneau","year":"2002","unstructured":"Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800\u20134. https:\/\/doi.org\/10.1164\/ajrccm.165.6.2106079FromNLMMedline.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2157_CR121","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/nejmoa020204","volume":"347","author":"H Olschewski","year":"2002","unstructured":"Olschewski H, Simonneau G, Gali\u00e8 N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, et al. Inhaled Iloprost for Severe Pulmonary Hypertension. N Engl J Med. 2002;347(5):322\u20139. https:\/\/doi.org\/10.1056\/nejmoa020204.","journal-title":"N Engl J Med"},{"issue":"12","key":"2157_CR122","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/s0735-1097(03)00463-7","volume":"41","author":"RJ Barst","year":"2003","unstructured":"Barst RJ, McGoon M, McLaughlin V, Tapson V, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(12):2119\u201325. https:\/\/doi.org\/10.1016\/s0735-1097(03)00463-7.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2157_CR123","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12325-023-02769-7FromNLMMedline","volume":"41","author":"J Barbera","year":"2024","unstructured":"Barbera J, Jansa P, Klings E, Ristic A, Keogh A, Solum D, Rao Y, Grover R, Saib I, Sood N. Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension. Adv Ther. 2024;41(3):1062\u201374. https:\/\/doi.org\/10.1007\/s12325-023-02769-7FromNLMMedline.","journal-title":"Adv Ther"},{"issue":"3","key":"2157_CR124","doi-asserted-by":"publisher","first-page":"H361","DOI":"10.1152\/ajpheart.00843.2013","volume":"307","author":"MA Borgdorff","year":"2014","unstructured":"Borgdorff MA, Bartelds B, Dickinson MG, van Wiechen MPH, Steendijk P, de Vroomen M, Berger RMF. Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload. Am J Physiology-Heart Circulatory Physiology. 2014;307(3):H361\u20139. https:\/\/doi.org\/10.1152\/ajpheart.00843.2013.","journal-title":"Am J Physiology-Heart Circulatory Physiology"},{"issue":"4","key":"2157_CR125","doi-asserted-by":"publisher","first-page":"e002729","DOI":"10.1161\/circheartfailure.115.002729","volume":"9","author":"I Hussain","year":"2016","unstructured":"Hussain I, Mohammed SF, Forfia PR, Lewis GD, Borlaug BA, Gallup DS, Redfield MM. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure. 2016;9(4):e002729. https:\/\/doi.org\/10.1161\/circheartfailure.115.002729.","journal-title":"Circulation: Heart Failure"},{"issue":"2","key":"2157_CR126","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1183\/09031936.00188013","volume":"45","author":"J Gomez-Arroyo","year":"2015","unstructured":"Gomez-Arroyo J, Sakagami M, Syed AA, Farkas L, Van Tassell B, Kraskauskas D, Mizuno S, Abbate A, Bogaard HJ, Byron PR, et al. Iloprost reverses established fibrosis in experimental right ventricular failure. Eur Respir J. 2015;45(2):449\u201362. https:\/\/doi.org\/10.1183\/09031936.00188013.","journal-title":"Eur Respir J"},{"key":"2157_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3293584","volume":"2018","author":"N Rai","year":"2018","unstructured":"Rai N, Veeroju S, Schymura Y, Janssen W, Wietelmann A, Kojonazarov B, Weissmann N, Stasch J-P, Ghofrani HA, Seeger W, et al. Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. Biomed Res Int. 2018;2018:1\u20139. https:\/\/doi.org\/10.1155\/2018\/3293584.","journal-title":"Biomed Res Int"},{"issue":"12","key":"2157_CR128","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/nejmoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, Gali\u00e8 N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan Therapy for Pulmonary Arterial Hypertension. N Engl J Med. 2002;346(12):896\u2013903. https:\/\/doi.org\/10.1056\/nejmoa012212.","journal-title":"N Engl J Med"},{"issue":"9","key":"2157_CR129","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/nejmoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery J-L, Gr\u00fcnig E, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834\u201344. https:\/\/doi.org\/10.1056\/nejmoa1413687.","journal-title":"N Engl J Med"},{"issue":"9","key":"2157_CR130","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/nejmoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Gali\u00e8 N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med. 2013;369(9):809\u201318. https:\/\/doi.org\/10.1056\/nejmoa1213917.","journal-title":"N Engl J Med"},{"key":"2157_CR131","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/dhps.s372239","volume":"16","author":"S Cassady","year":"2024","unstructured":"Cassady S, Almario JA, Ramani G. Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date. Drug, Healthcare and Patient Safety. 2024;16:51\u20139. https:\/\/doi.org\/10.2147\/dhps.s372239.","journal-title":"Drug, Healthcare and Patient Safety"},{"issue":"11","key":"2157_CR132","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1007\/s12325-022-02296-x","volume":"39","author":"FA Ismat","year":"2022","unstructured":"Ismat FA, Usansky HH, Villa R, Zou J, Teper A. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study. Adv Ther. 2022;39(11):5144\u201357. https:\/\/doi.org\/10.1007\/s12325-022-02296-x.","journal-title":"Adv Ther"},{"issue":"166","key":"2157_CR133","doi-asserted-by":"publisher","first-page":"220061","DOI":"10.1183\/16000617.0061-2022","volume":"31","author":"RL Benza","year":"2022","unstructured":"Benza RL, Langleben D, Hemnes AR, Vonk Noordegraaf A, Rosenkranz S, Thenappan T, Hassoun PM, Preston IR, Ghio S, Badagliacca R, et al. Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2022;31(166):220061. https:\/\/doi.org\/10.1183\/16000617.0061-2022.","journal-title":"Eur Respir Rev"},{"key":"2157_CR134","doi-asserted-by":"publisher","unstructured":"Cassady SJ, Soldin D, Ramani GV. Novel and emerging therapies in pulmonary arterial hypertension. Front Drug Discovery 2022;2. https:\/\/doi.org\/10.3389\/fddsv.2022.1022971.","DOI":"10.3389\/fddsv.2022.1022971"},{"issue":"10","key":"2157_CR135","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1161\/circulationaha.112.000765","volume":"127","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Gali\u00e9 N, G\u00f3mez-S\u00e1nchez MA, Grimminger F, Gr\u00fcnig E, Hassoun PM, et al. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation. 2013;127(10):1128\u201338. https:\/\/doi.org\/10.1161\/circulationaha.112.000765.","journal-title":"Circulation"},{"issue":"4","key":"2157_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20458940211052823","volume":"11","author":"MR Wilkins","year":"2021","unstructured":"Wilkins MR, McKie MA, Law M, Roussakis AA, Harbaum L, Church C, Coghlan JG, Condliffe R, Howard LS, Kiely DG, et al. Positioning imatinib for pulmonary arterial hypertension: A phase I\/II design comprising dose finding and single-arm efficacy. Pulmonary Circulation. 2021;11(4):1\u201312. https:\/\/doi.org\/10.1177\/20458940211052823.","journal-title":"Pulmonary Circulation"},{"issue":"7","key":"2157_CR137","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S2213-2600(24)00072-9FromNLMMedline","volume":"12","author":"RP Frantz","year":"2024","unstructured":"Frantz RP, McLaughlin VV, Sahay S, Escribano Subias P, Zolty RL, Benza RL, Channick RN, Chin KM, Hemnes AR, Howard LS, et al. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomized, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2024;12(7):523\u201334. https:\/\/doi.org\/10.1016\/S2213-2600(24)00072-9FromNLMMedline.","journal-title":"Lancet Respir Med"},{"issue":"13","key":"2157_CR138","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/nejmoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021;384(13):1204\u201315. https:\/\/doi.org\/10.1056\/nejmoa2024277.","journal-title":"N Engl J Med"},{"issue":"16","key":"2157_CR139","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558FromNLMMedline","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grunig E, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388(16):1478\u201390. https:\/\/doi.org\/10.1056\/NEJMoa2213558FromNLMMedline.","journal-title":"N Engl J Med"},{"issue":"4","key":"2157_CR140","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1164\/rccm.201403-0483oc","volume":"190","author":"KM Mair","year":"2014","unstructured":"Mair KM, Wright AF, Duggan N, Rowlands DJ, Hussey MJ, Roberts S, Fullerton J, Nilsen M, Loughlin L, Thomas M, et al. Sex-Dependent Influence of Endogenous Estrogen in Pulmonary Hypertension. Am J Respir Crit Care Med. 2014;190(4):456\u201367. https:\/\/doi.org\/10.1164\/rccm.201403-0483oc.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"2157_CR141","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.micinf.2014.10.001FromNLMMedline","volume":"16","author":"T Palmai-Pallag","year":"2014","unstructured":"Palmai-Pallag T, Bachrati CZ. Inflammation-induced DNA damage and damage-induced inflammation: a vicious cycle. Microbes Infect. 2014;16(10):822\u201332. https:\/\/doi.org\/10.1016\/j.micinf.2014.10.001FromNLMMedline.","journal-title":"Microbes Infect"},{"issue":"6","key":"2157_CR142","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/ijms17060990","volume":"17","author":"B Ranchoux","year":"2016","unstructured":"Ranchoux B, Meloche J, Paulin R, Boucherat O, Provencher S, Bonnet S. DNA Damage and Pulmonary Hypertension. Int J Mol Sci. 2016;17(6):990. https:\/\/doi.org\/10.3390\/ijms17060990.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2157_CR143","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/genes11101224","volume":"11","author":"S Sharma","year":"2020","unstructured":"Sharma S, Aldred MA. DNA Damage and Repair in Pulmonary Arterial Hypertension. Genes. 2020;11(10):1224. https:\/\/doi.org\/10.3390\/genes11101224.","journal-title":"Genes"},{"issue":"7","key":"2157_CR144","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008FromNLMMedline","volume":"37","author":"C Xue","year":"2021","unstructured":"Xue C, Greene EC. DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing. Trends Genet. 2021;37(7):639\u201356. https:\/\/doi.org\/10.1016\/j.tig.2021.02.008FromNLMMedline.","journal-title":"Trends Genet"},{"key":"2157_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/8217105","volume":"2017","author":"JC Grignola","year":"2017","unstructured":"Grignola JC, Domingo E. Acute Right Ventricular Dysfunction in Intensive Care Unit. Biomed Res Int. 2017;2017:1\u201315. https:\/\/doi.org\/10.1155\/2017\/8217105.","journal-title":"Biomed Res Int"},{"issue":"3","key":"2157_CR146","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ejhf.478","volume":"18","author":"VP Harjola","year":"2016","unstructured":"Harjola VP, Mebazaa A, \u010celutkien\u0117 J, Bettex D, Bueno H, Chioncel O, Crespo-Leiro MG, Falk V, Filippatos G, Gibbs S, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016;18(3):226\u201341. https:\/\/doi.org\/10.1002\/ejhf.478.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2157_CR147","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, Huisman MV, Humbert M, Jennings CS, Jim\u00e9nez D, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405.","journal-title":"Eur Heart J"},{"issue":"14","key":"2157_CR148","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/nejm199304083281401","volume":"328","author":"M Zehender","year":"1993","unstructured":"Zehender M, Kasper W, Kauder E, Schonthaler M, Geibel A, Olschewski M, Just H. Right Ventricular Infarction as an Independent Predictor of Prognosis after Acute Inferior Myocardial Infarction. N Engl J Med. 1993;328(14):981\u20138. https:\/\/doi.org\/10.1056\/nejm199304083281401.","journal-title":"N Engl J Med"},{"issue":"2","key":"2157_CR149","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/resp.12881","volume":"22","author":"D Winterton","year":"2017","unstructured":"Winterton D, Bailey M, Pilcher D, Landoni G, Bellomo R. Characteristics, incidence and outcome of patients admitted to intensive care because of pulmonary embolism. Respirology. 2017;22(2):329\u201337. https:\/\/doi.org\/10.1111\/resp.12881.","journal-title":"Respirology"},{"issue":"8","key":"2157_CR150","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1097\/01.CCM.0000275266.33910.8DFromNLMMedline","volume":"35","author":"F Kerbaul","year":"2007","unstructured":"Kerbaul F, Gariboldi V, Giorgi R, Mekkaoui C, Guieu R, Fesler P, Gouin F, Brimioulle S, Collart F. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med. 2007;35(8):1948\u201354. https:\/\/doi.org\/10.1097\/01.CCM.0000275266.33910.8DFromNLMMedline.","journal-title":"Crit Care Med"},{"issue":"6","key":"2157_CR151","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/BF01710657FromNLMMedline","volume":"20","author":"C Martin","year":"1994","unstructured":"Martin C, Perrin G, Saux P, Papazian L, Gouin F. Effects of norepinephrine on right ventricular function in septic shock patients. Intensive Care Med. 1994;20(6):444\u20137. https:\/\/doi.org\/10.1007\/BF01710657FromNLMMedline.","journal-title":"Intensive Care Med"},{"issue":"4","key":"2157_CR152","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.bja.2019.01.014","volume":"122","author":"Y Sugawara","year":"2019","unstructured":"Sugawara Y, Mizuno Y, Oku S, Goto T. Effects of vasopressin during a pulmonary hypertensive crisis induced by acute hypoxia in a rat model of pulmonary hypertension. British Journal of Anesthesia. 2019;122(4):437\u201347. https:\/\/doi.org\/10.1016\/j.bja.2019.01.014.","journal-title":"British Journal of Anesthesia"},{"issue":"4","key":"2157_CR153","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1097\/CCM.0000000000004243FromNLMMedline","volume":"48","author":"J Schultz","year":"2020","unstructured":"Schultz J, Andersen A, Lyhne MD, Arcanjo DDR, Kjaergaard B, Simonsen U, Nielsen-Kudsk JE. Terlipressin Increases Systemic and Lowers Pulmonary Arterial Pressure in Experimental Acute Pulmonary Embolism. Crit Care Med. 2020;48(4):e308\u201315. https:\/\/doi.org\/10.1097\/CCM.0000000000004243FromNLMMedline.","journal-title":"Crit Care Med"},{"issue":"2 Pt 2","key":"2157_CR154","doi-asserted-by":"publisher","first-page":"F274","DOI":"10.1152\/ajprenal.1989.256.2.F274FromNLMMedline","volume":"256","author":"RM Edwards","year":"1989","unstructured":"Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol. 1989;256(2 Pt 2):F274-278. https:\/\/doi.org\/10.1152\/ajprenal.1989.256.2.F274FromNLMMedline.","journal-title":"Am J Physiol"},{"issue":"1","key":"2157_CR155","doi-asserted-by":"publisher","first-page":"H224","DOI":"10.1152\/ajpheart.00507.2018","volume":"316","author":"PM Cowley","year":"2019","unstructured":"Cowley PM, Wang G, Swigart PM, Raghunathan A, Reddy N, Dulam P, Lovett DH, Simpson PC, Baker AJ. Reversal of right ventricular failure by chronic \u03b1<sub>1A<\/sub>-subtype adrenergic agonist therapy. American Journal of Physiology-Heart and Circulatory Physiology. 2019;316(1):H224\u201332. https:\/\/doi.org\/10.1152\/ajpheart.00507.2018.","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"issue":"3","key":"2157_CR156","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1378\/chest.100.3.796","volume":"100","author":"LJ Hirsch","year":"1991","unstructured":"Hirsch LJ, Rooney MW, Wat SS, Kleinmann B, Mathru M. Norepinephrine and Phenylephrine Effects on Right Ventricular Function in Experimental Canine Pulmonary Embolism. Chest. 1991;100(3):796\u2013801. https:\/\/doi.org\/10.1378\/chest.100.3.796.","journal-title":"Chest"},{"issue":"2","key":"2157_CR157","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12265-021-10158-0","volume":"15","author":"ER Kaso","year":"2022","unstructured":"Kaso ER, Pan JA, Salerno M, Kadl A, Aldridge C, Haskal ZJ, Kennedy JLW, Mazimba S, Mihalek AD, Teman NR, et al. Venoarterial Extracorporeal Membrane Oxygenation for Acute Massive Pulmonary Embolism: a Meta-Analysis and Call to Action. J Cardiovasc Transl Res. 2022;15(2):258\u201367. https:\/\/doi.org\/10.1007\/s12265-021-10158-0.","journal-title":"J Cardiovasc Transl Res"},{"issue":"4","key":"2157_CR158","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1177\/02676591231177909FromNLMMedline","volume":"39","author":"S Cardona","year":"2024","unstructured":"Cardona S, Downing JV, Witting MD, Haase DJ, Powell EK, Dahi S, Pasrija C, Tran QK. Venoarterial Extracorporeal Membrane Oxygenation With or Without Advanced Intervention for Massive Pulmonary Embolism. Perfusion. 2024;39(4):665\u201374. https:\/\/doi.org\/10.1177\/02676591231177909FromNLMMedline.","journal-title":"Perfusion"},{"issue":"7","key":"2157_CR159","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/ehjacc\/zuac063","volume":"11","author":"MK Kanwar","year":"2022","unstructured":"Kanwar MK, Everett KD, Gulati G, Brener MI, Kapur NK. Epidemiology and management of right ventricular-predominant heart failure and shock in the cardiac intensive care unit. Eur Heart J Acute Cardiovasc Care. 2022;11(7):584\u201394. https:\/\/doi.org\/10.1093\/ehjacc\/zuac063.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"8","key":"2157_CR160","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/17434440.2019.1635006","volume":"16","author":"S Shimada","year":"2019","unstructured":"Shimada S, Nawata K, Kinoshita O, Ono M. Mechanical circulatory support for the right ventricle in combination with a left ventricular assist device. Expert Rev Med Devices. 2019;16(8):663\u201373. https:\/\/doi.org\/10.1080\/17434440.2019.1635006.","journal-title":"Expert Rev Med Devices"},{"key":"2157_CR161","doi-asserted-by":"publisher","first-page":"53","DOI":"10.12659\/msmbr.898897","volume":"22","author":"B Schmack","year":"2016","unstructured":"Schmack B, Weymann A, Popov A-F, Patil NP, Sabashnikov A, Kremer J, Farag M, Brcic A, Lichtenstern C, Karck M, et al. Concurrent Left Ventricular Assist Device (LVAD) Implantation and Percutaneous Temporary RVAD Support via CardiacAssist Protek-Duo TandemHeart to Preempt Right Heart Failure. Med Sci Monit Basic Res. 2016;22:53\u20137. https:\/\/doi.org\/10.12659\/msmbr.898897.","journal-title":"Med Sci Monit Basic Res"},{"issue":"36","key":"2157_CR162","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368FromNLMMedline","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368FromNLMMedline.","journal-title":"Eur Heart J"},{"key":"2157_CR163","unstructured":"Favaloro RR, Bertolotti A, Diez M, Favaloro L, Gomez C, Peradejordi M, Trentadue J, Hellman L, Arzani Y, Otero PV. Adequate systemic perfusion maintained by a CentriMag during acute heart failure. Tex Heart Inst J 2008;35(3):334\u2013339. From NLM Medline."},{"key":"2157_CR164","doi-asserted-by":"publisher","first-page":"m2177","DOI":"10.1136\/bmj.m2177FromNLMMedline","volume":"370","author":"L Duffett","year":"2020","unstructured":"Duffett L, Castellucci LA, Forgie MA. Pulmonary embolism: update on management and controversies. BMJ. 2020;370:m2177. https:\/\/doi.org\/10.1136\/bmj.m2177FromNLMMedline.","journal-title":"BMJ"},{"key":"2157_CR165","doi-asserted-by":"publisher","unstructured":"Gong M, Jiang R, Zhao B, Kong J, Liu Z, Qian C, He X, Gu J. Relationship between vascular access and angulation of vena cava filter at placement and retrieval: a multicenter retrospective cohort study. Therapeutic Adv Chronic Dis 2023;14. https:\/\/doi.org\/10.1177\/20406223231200254.","DOI":"10.1177\/20406223231200254"},{"issue":"5","key":"2157_CR166","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1161\/circulationaha.117.031544","volume":"137","author":"M Brida","year":"2018","unstructured":"Brida M, Diller G-P, Gatzoulis MA. Systemic Right Ventricle in Adults With Congenital Heart Disease. Circulation. 2018;137(5):508\u201318. https:\/\/doi.org\/10.1161\/circulationaha.117.031544.","journal-title":"Circulation"},{"key":"2157_CR167","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-023-03381-w","author":"WR Miranda","year":"2024","unstructured":"Miranda WR, Jain CC, Egbe AC, Reddy YN, Dearani JA, Hagler DJ, Connolly HM. Hemodynamics in Adults with Systemic Right Ventricles: Differences Between Congenitally Corrected and Complete Transposition of the Great Arteries. Pediatr Cardiol. 2024. https:\/\/doi.org\/10.1007\/s00246-023-03381-w.","journal-title":"Pediatr Cardiol"},{"key":"2157_CR168","doi-asserted-by":"publisher","unstructured":"Ladouceur M, Segura de la Cal T, Gaye B, Valentin E, Ly R, Iserin L, Legendre A, Mousseaux E, Li W, Rafiq I et al. Effect of medical treatment on heart failure incidence in patients with a systemic right ventricle. Heart 2021;107 (17):1384\u20131389. https:\/\/doi.org\/10.1136\/heartjnl-2020-318787","DOI":"10.1136\/heartjnl-2020-318787"},{"issue":"6","key":"2157_CR169","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s10741-020-09982-4","volume":"26","author":"YJHJ Taverne","year":"2021","unstructured":"Taverne YJHJ, Sadeghi A, Bartelds B, Bogers AJJC, Merkus D. Right ventricular phenotype, function, and failure: a journey from evolution to clinics. Heart Fail Rev. 2021;26(6):1447\u201366. https:\/\/doi.org\/10.1007\/s10741-020-09982-4.","journal-title":"Heart Fail Rev"},{"key":"2157_CR170","doi-asserted-by":"publisher","unstructured":"Sabbah BN, Arabi TZ, Shafqat A, Abdul Rab S, Razak A, Albert-Brotons DC. Heart failure in systemic right ventricle: Mechanisms and therapeutic options. Front Cardiovas Med 2023;9. https:\/\/doi.org\/10.3389\/fcvm.2022.1064196.","DOI":"10.3389\/fcvm.2022.1064196"},{"key":"2157_CR171","doi-asserted-by":"publisher","unstructured":"Chaix M-A, Dore A, Mond\u00e9sert B, Mongeon F-P, Roy V, Desrosiers-Gagnon C, Guertin M-C, White M, Ibrahim R, O\u2019Meara E et al. Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial. European Heart Journal 2024;45(16):1481\u20131483. https:\/\/doi.org\/10.1093\/eurheartj\/ehad890.","DOI":"10.1093\/eurheartj\/ehad890"},{"key":"2157_CR172","doi-asserted-by":"publisher","unstructured":"Das, B. B. Unlocking the Potential: Angiotensin Receptor Neprilysin and Sodium Glucose Co-Transporter 2 Inhibitors for Right Ventricle Dysfunction in Heart Failure. Medicina (Kaunas) 2024;60(7). https:\/\/doi.org\/10.3390\/medicina60071112 From NLM Medline.","DOI":"10.3390\/medicina60071112"},{"key":"2157_CR173","doi-asserted-by":"publisher","first-page":"131152","DOI":"10.1016\/j.ijcard.2023.131152FromNLMMedline","volume":"387","author":"K Andi","year":"2023","unstructured":"Andi K, Abozied O, Miranda WR, Anderson JH, Connolly HM, Jain CC, Burchill LJ, Egbe AC. Clinical benefits of angiotensin receptor-Neprilysin inhibitor in adults with congenital heart disease. Int J Cardiol. 2023;387:131152. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131152FromNLMMedline.","journal-title":"Int J Cardiol"},{"issue":"21","key":"2157_CR174","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1136\/heartjnl-2020-318074FromNLMMedline","volume":"107","author":"TE Zandstra","year":"2021","unstructured":"Zandstra TE, Nederend M, Jongbloed MRM, Kies P, Vliegen HW, Bouma BJ, Tops LF, Schalij MJ, Egorova AD. Sacubitril\/valsartan in the treatment of systemic right ventricular failure. Heart. 2021;107(21):1725\u201330. https:\/\/doi.org\/10.1136\/heartjnl-2020-318074FromNLMMedline.","journal-title":"Heart"},{"issue":"20","key":"2157_CR175","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1136\/heartjnl-2022-322332FromNLMPublisher","volume":"109","author":"M Nederend","year":"2023","unstructured":"Nederend M, Kies P, Regeer MV, Vliegen HW, Mertens BJ, Robbers-Visser D, Bouma BJ, Tops LF, Schalij MJ, Jongbloed MRM, et al. Tolerability and beneficial effects of sacubitril\/valsartan on systemic right ventricular failure. Heart. 2023;109(20):1525\u201332. https:\/\/doi.org\/10.1136\/heartjnl-2022-322332FromNLMPublisher.","journal-title":"Heart"},{"key":"2157_CR176","doi-asserted-by":"publisher","unstructured":"Yan L, Loh JK, Tan JL. Sacubitril\/valsartan for heart failure in patients with complex adult congenital heart disease \u2013 Experience from a tertiary center in Singapore. Int J Cardiology Congenital Heart Dis 2021;6. https:\/\/doi.org\/10.1016\/j.ijcchd.2021.100268.","DOI":"10.1016\/j.ijcchd.2021.100268"},{"issue":"4","key":"2157_CR177","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jchf.2024.01.006FromNLMMedline","volume":"12","author":"F Fusco","year":"2024","unstructured":"Fusco F, Scognamiglio G, Abbate M, Merola A, Grimaldi N, Ciriello GD, Sarubbi B. Dapagliflozin in Patients With a Failing Systemic Right Ventricle: Results From the DAPA-SERVE Trial. JACC Heart Fail. 2024;12(4):789\u201391. https:\/\/doi.org\/10.1016\/j.jchf.2024.01.006FromNLMMedline.","journal-title":"JACC Heart Fail"},{"issue":"15","key":"2157_CR178","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jacc.2024.02.017FromNLMMedline","volume":"83","author":"RML Neijenhuis","year":"2024","unstructured":"Neijenhuis RML, MacDonald ST, Zemrak F, Mertens BJA, Dinsdale A, Hunter A, Walker NL, Swan L, Reddy S, Rotmans JI, et al. Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease. J Am Coll Cardiol. 2024;83(15):1403\u201314. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.017FromNLMMedline.","journal-title":"J Am Coll Cardiol"},{"key":"2157_CR179","doi-asserted-by":"publisher","first-page":"100495","DOI":"10.1016\/j.ijcchd.2024.100495","volume":"15","author":"A Kheiwa","year":"2024","unstructured":"Kheiwa A, Ssembajjwe B, Chatta P, Nageotte S, Abramov D. Safety of SGLT-2 inhibitors in the management of heart failure in the adult congenital heart disease patient population. International Journal of Cardiology Congenital Heart Disease. 2024;15:100495. https:\/\/doi.org\/10.1016\/j.ijcchd.2024.100495.","journal-title":"International Journal of Cardiology Congenital Heart Disease"},{"issue":"6","key":"2157_CR180","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cardfail.2023.03.011","volume":"29","author":"J Saef","year":"2023","unstructured":"Saef J, Sundaravel S, Ortega-Legaspi J, Vaikunth S. Safety and Treatment Experience With Sodium\/glucose Cotransporter-2 Inhibitors in Adult Patients With Congenital Heart Disease. J Cardiac Fail. 2023;29(6):974\u20135. https:\/\/doi.org\/10.1016\/j.cardfail.2023.03.011.","journal-title":"J Cardiac Fail"},{"key":"2157_CR181","doi-asserted-by":"publisher","unstructured":"Snigdha Karnakoti KA, William R. Miranda C. Charles Jain, Luke J Burchill, Maan Jokhadar, Heidi Connolly, Alexander C Egbe. Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Use in Adults With Congenital Heart Disease. CJC Peditric Congenital Heart Disease 2024. https:\/\/doi.org\/10.1016\/j.cjcpc.2024.02.001.","DOI":"10.1016\/j.cjcpc.2024.02.001"},{"issue":"2","key":"2157_CR182","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.chest.2021.09.023","volume":"161","author":"AM Marra","year":"2022","unstructured":"Marra AM, Sherman AE, Salzano A, Guazzi M, Saggar R, Squire IB, Cittadini A, Channick RN, Bossone E. Right Side of the Heart Pulmonary Circulation Unit Involvement in Left-Sided Heart Failure. Chest. 2022;161(2):535\u201351. https:\/\/doi.org\/10.1016\/j.chest.2021.09.023.","journal-title":"Chest"},{"issue":"3","key":"2157_CR183","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cardfail.2011.12.003","volume":"18","author":"T Damy","year":"2012","unstructured":"Damy T, Kallvikbacka-Bennett A, Goode K, Khaleva O, Lewinter C, Hobkirk J, Nikitin NP, Dubois-Rand\u00e9 J-L, Hittinger L, Clark AL, et al. Prevalence of, Associations With, and Prognostic Value of Tricuspid Annular Plane Systolic Excursion (TAPSE) Among Out-Patients Referred for the Evaluation of Heart Failure. J Cardiac Fail. 2012;18(3):216\u201325. https:\/\/doi.org\/10.1016\/j.cardfail.2011.12.003.","journal-title":"J Cardiac Fail"},{"issue":"2\u20133","key":"2157_CR184","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3909\/ricm0602","volume":"13","author":"MAR Rodr\u00edguez","year":"2012","unstructured":"Rodr\u00edguez MAR, Alonso D, Mart\u00edn JM, L\u00f3pez-Benito ML-B, Garrote C, Olalla-G\u00f3mez CO-G, Iglesias-Garriz I. Contribution of Right Ventricular Dysfunction to Heart Failure Mortality: A Meta-Analysis. Rev Cardiovasc Med. 2012;13(2\u20133):62\u20139. https:\/\/doi.org\/10.3909\/ricm0602.","journal-title":"Rev Cardiovasc Med"},{"key":"2157_CR185","doi-asserted-by":"publisher","unstructured":"Shaker MM, Taha HS, Kandil HI, Kamal HM, Mahrous HA, Elamragy AA. Prognostic significance of right ventricular dysfunction in patients presenting with acute left-sided heart failure. Egyptian Heart J 2024;76(1). https:\/\/doi.org\/10.1186\/s43044-023-00432-8.","DOI":"10.1186\/s43044-023-00432-8"},{"issue":"4","key":"2157_CR186","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/s0735-1097(01)01479-6FromNLMMedline","volume":"38","author":"G Marenzi","year":"2001","unstructured":"Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001;38(4):963\u20138. https:\/\/doi.org\/10.1016\/s0735-1097(01)01479-6FromNLMMedline.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2157_CR187","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/ehjacc\/zuad013","volume":"12","author":"P Lim","year":"2023","unstructured":"Lim P, Sharifi J, Huguet R, Gallet R, Aouate D. Repetitive use of levosimendan in severe functional tricuspid regurgitation. Eur Heart J Acute Cardiovasc Care. 2023;12(5):336\u20137. https:\/\/doi.org\/10.1093\/ehjacc\/zuad013.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"1","key":"2157_CR188","doi-asserted-by":"publisher","first-page":"e15859","DOI":"10.1371\/journal.pone.0015859","volume":"6","author":"JD Baandrup","year":"2011","unstructured":"Baandrup JD, Markvardsen LH, Peters CD, Schou UK, Jensen JL, Magnusson NE, \u00d8rntoft TF, Kruh\u00f8ffer M, Simonsen U. Pressure Load: The Main Factor for Altered Gene Expression in Right Ventricular Hypertrophy in Chronic Hypoxic Rats. PLoS ONE. 2011;6(1):e15859. https:\/\/doi.org\/10.1371\/journal.pone.0015859.","journal-title":"PLoS ONE"},{"issue":"6","key":"2157_CR189","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/cpf.12726FromNLMMedline","volume":"41","author":"M Correale","year":"2021","unstructured":"Correale M, Mazzeo P, Magnesa M, Fortunato M, Tricarico L, Leopizzi A, Mallardi A, Mennella R, Tucci S, Brunetti ND. Predictors of right ventricular function improvement with sacubitril\/valsartan in a real-life population of patients with chronic heart failure. Clin Physiol Funct Imaging. 2021;41(6):505\u201313. https:\/\/doi.org\/10.1111\/cpf.12726FromNLMMedline.","journal-title":"Clin Physiol Funct Imaging"},{"key":"2157_CR190","doi-asserted-by":"publisher","unstructured":"Luo T, Wu H, Zhu W, Zhang L, Huang Y, Yang X. Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension. Respiratory Medicine 2024;227. https:\/\/doi.org\/10.1016\/j.rmed.2024.107631.","DOI":"10.1016\/j.rmed.2024.107631"},{"issue":"17","key":"2157_CR191","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/circulationaha.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, Lamba S, Bhatt K, Brush J, Civitello A, et al. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure. Circulation. 2021;143(17):1673\u201386. https:\/\/doi.org\/10.1161\/circulationaha.120.052503.","journal-title":"Circulation"},{"issue":"1","key":"2157_CR192","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10554-020-01973-8","volume":"37","author":"M Yener\u00e7a\u011f","year":"2021","unstructured":"Yener\u00e7a\u011f M, Arslan U, Dereli S, \u00c7oksevim M, Do\u011fdu\u015f M, Kaya A. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction. Int J Cardiovasc Imaging. 2021;37(1):165\u201373. https:\/\/doi.org\/10.1007\/s10554-020-01973-8.","journal-title":"Int J Cardiovasc Imaging"},{"key":"2157_CR193","doi-asserted-by":"publisher","unstructured":"Mustapic I, Bakovic D, Susilovic Grabovac Z, Borovac JA. Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction. J Clin Med 2022;12(1). https:\/\/doi.org\/10.3390\/jcm12010042.","DOI":"10.3390\/jcm12010042"},{"key":"2157_CR194","doi-asserted-by":"publisher","unstructured":"Axelsen JS, Nielsen-Kudsk AH, Schwab J, Ringgaard S, Nielsen-Kudsk JE, De Man FS, Andersen A, Andersen S. Effects of empagliflozin on right ventricular adaptation to pressure overload. Front Cardiovascular Med 2023;10. https:\/\/doi.org\/10.3389\/fcvm.2023.1302265.","DOI":"10.3389\/fcvm.2023.1302265"},{"key":"2157_CR195","doi-asserted-by":"publisher","unstructured":"Yang Z, Li T, Xian J, Chen J, Huang Y, Zhang Q, Lin X, Lu H, Lin Y. <scp>SGLT2<\/scp> inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the <scp>HIF<\/scp>\u20102\u03b1 signaling pathway in arrhythmogenic cardiomyopathy. FASEB J 2022;36(7). https:\/\/doi.org\/10.1096\/fj.202200243r.","DOI":"10.1096\/fj.202200243r"},{"key":"2157_CR196","doi-asserted-by":"publisher","unstructured":"Bravo CA, Navarro AG, Dhaliwal KK, Khorsandi M, Keenan JE, Mudigonda P, O'Brien KD, Mahr C. Right heart failure after left ventricular assist device: From mechanisms to treatments. Front Cardiovascular Med 2022;9. https:\/\/doi.org\/10.3389\/fcvm.2022.1023549.","DOI":"10.3389\/fcvm.2022.1023549"},{"issue":"6","key":"2157_CR197","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/ejechocard\/jep052","volume":"10","author":"S Puwanant","year":"2009","unstructured":"Puwanant S, Priester TC, Mookadam F, Bruce CJ, Redfield MM, Chandrasekaran K. Right ventricular function in patients with preserved and reduced ejection fraction heart failure. Eur J Echocardiogr. 2009;10(6):733\u20137. https:\/\/doi.org\/10.1093\/ejechocard\/jep052.","journal-title":"Eur J Echocardiogr"},{"key":"2157_CR198","doi-asserted-by":"publisher","unstructured":"Gorter TM, Van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJS Crespo\u2010Leiro MG, Guazzi M, Harjola VP, Heymans S et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European J Heart Failure 2018;20(1):16\u201337. https:\/\/doi.org\/10.1002\/ejhf.1029","DOI":"10.1002\/ejhf.1029"},{"issue":"12","key":"2157_CR199","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/ejhf.873","volume":"19","author":"L Bosch","year":"2017","unstructured":"Bosch L, Lam CSP, Gong L, Chan SP, Sim D, Yeo D, Jaufeerally F, Leong KTG, Ong HY, Ng TP, et al. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1664\u201371. https:\/\/doi.org\/10.1002\/ejhf.873.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2157_CR200","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jacc.2023.05.010","volume":"82","author":"RM Inciardi","year":"2023","unstructured":"Inciardi RM, Abanda M, Shah AM, Cikes M, Claggett B, Skali H, Vaduganathan M, Prasad N, Litwin S, Merkely B, et al. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2023;82(6):489\u201399. https:\/\/doi.org\/10.1016\/j.jacc.2023.05.010.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2157_CR201","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ejhf.664","volume":"19","author":"S Ghio","year":"2017","unstructured":"Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, Temporelli PL, Rossi A, Faggiano P, Traversi E, et al. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail. 2017;19(7):873\u20139. https:\/\/doi.org\/10.1002\/ejhf.664.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2157_CR202","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67\u2013119. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317.","journal-title":"Eur Heart J"},{"issue":"3","key":"2157_CR203","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00246-022-02960-7FromNLMMedline","volume":"44","author":"B Das","year":"2023","unstructured":"Das B, Deshpande S, Akam-Venkata J, Shakti D, Moskowitz W, Lipshultz SE. Heart Failure with Preserved Ejection Fraction in Children. Pediatr Cardiol. 2023;44(3):513\u201329. https:\/\/doi.org\/10.1007\/s00246-022-02960-7FromNLMMedline.","journal-title":"Pediatr Cardiol"},{"issue":"15","key":"2157_CR204","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38","author":"B Pieske","year":"2017","unstructured":"Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, Ponikowski P, Shah SJ, Solomon SD, Scalise A-V, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119\u201327. https:\/\/doi.org\/10.1093\/eurheartj\/ehw593.","journal-title":"Eur Heart J"},{"issue":"11","key":"2157_CR205","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.healun.2016.07.015FromNLMMedline","volume":"35","author":"KT Finch","year":"2016","unstructured":"Finch KT, Stratton EA, Farber HW. Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study. J Heart Lung Transplant. 2016;35(11):1370\u20133. https:\/\/doi.org\/10.1016\/j.healun.2016.07.015FromNLMMedline.","journal-title":"J Heart Lung Transplant"},{"issue":"9851","key":"2157_CR206","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6FromNLMMedline","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial. Lancet. 2012;380(9851):1387\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(12)61227-6FromNLMMedline.","journal-title":"Lancet"},{"key":"2157_CR207","doi-asserted-by":"publisher","unstructured":"Lu H, Inciardi RM, Abanda M, Shah AM, Cikes M, Claggett B, Prasad N, Lam CS, Redfield MM, McMurray JJ et al. Abstract 13706: Determinants of Right Ventricular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial Experience. Circulation 2023;148(Suppl_1). https:\/\/doi.org\/10.1161\/circ.148.suppl_1.13706.","DOI":"10.1161\/circ.148.suppl_1.13706"},{"issue":"5","key":"2157_CR208","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/fjc.0000000000001477","volume":"82","author":"J Brockm\u00f6ller","year":"2023","unstructured":"Brockm\u00f6ller J, Ivanoski S, Hundack L, Blohm J-H, Januszewski M, Remppis BA, Burgdorf C. Clinical and Hemodynamic Improvement in Pulmonary Hypertension After Switching to Sacubitril\/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction. J Cardiovasc Pharmacol. 2023;82(5):419\u201325. https:\/\/doi.org\/10.1097\/fjc.0000000000001477.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"16","key":"2157_CR209","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824FromNLMMedline","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, et al. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation. 2021;144(16):1284\u201394. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056824FromNLMMedline.","journal-title":"Circulation"},{"key":"2157_CR210","doi-asserted-by":"publisher","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner\u2013La Rocca H-P, Choi D-J, Chopra V, Chuquiure-Valenzuela E et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England J Med 2021;385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","DOI":"10.1056\/NEJMoa2107038"},{"issue":"2","key":"2157_CR211","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1080\/21655979.2021.2017652FromNLMMedline","volume":"13","author":"T Qin","year":"2022","unstructured":"Qin T, Kong B, Dai C, Xiao Z, Fang J, Shuai W, Huang H. Protective effects of Dapagliflozin on the vulnerability of ventricular arrhythmia in rats with pulmonary artery hypertension induced by monocrotaline. Bioengineered. 2022;13(2):2697\u2013709. https:\/\/doi.org\/10.1080\/21655979.2021.2017652FromNLMMedline.","journal-title":"Bioengineered"},{"issue":"1","key":"2157_CR212","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-022-01614-5FromNLMMedline","volume":"21","author":"J Wu","year":"2022","unstructured":"Wu J, Liu T, Shi S, Fan Z, Hiram R, Xiong F, Cui B, Su X, Chang R, Zhang W, et al. Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling. Cardiovasc Diabetol. 2022;21(1):197. https:\/\/doi.org\/10.1186\/s12933-022-01614-5FromNLMMedline.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2157_CR213","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/jcm13020456","volume":"13","author":"M Varrenti","year":"2024","unstructured":"Varrenti M, Preda A, Frontera A, Baroni M, Gigli L, Vargiu S, Colombo G, Carbonaro M, Paolucci M, Giordano F, et al. Arrhythmogenic Cardiomyopathy: Definition, Classification and Arrhythmic Risk Stratification. J Clin Med. 2024;13(2):456. https:\/\/doi.org\/10.3390\/jcm13020456.","journal-title":"J Clin Med"},{"key":"2157_CR214","unstructured":"Fontaine G, Guiraudon G, Frank R, Tereau Y, Fillette F, Marcus FI, Chomette G, Grosgogeat Y. [Arrhythmogenic right ventricular dysplasia and Uhl's disease]. Arch Mal Coeur Vaiss 1982;75 (4):361\u2013371. From NLM Medline."},{"issue":"14","key":"2157_CR215","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1093\/eurheartj\/ehz669","volume":"41","author":"D Corrado","year":"2020","unstructured":"Corrado D, Van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A, Asimaki A, Basso C, Bauce B, Brunckhorst C, Bucciarelli-Ducci C, et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J. 2020;41(14):1414\u201329. https:\/\/doi.org\/10.1093\/eurheartj\/ehz669.","journal-title":"Eur Heart J"},{"issue":"7","key":"2157_CR216","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2217\/fca-2021-0148FromNLMMedline","volume":"18","author":"TN Maitz","year":"2022","unstructured":"Maitz TN, Gupta R, Persin K, Sundlof DW. Utilization of sacubitril-valsartan for right ventricular failure in a patient with arrhythmogenic right ventricular cardiomyopathy. Future Cardiol. 2022;18(7):547\u201352. https:\/\/doi.org\/10.2217\/fca-2021-0148FromNLMMedline.","journal-title":"Future Cardiol"},{"key":"2157_CR217","doi-asserted-by":"publisher","first-page":"6032631","DOI":"10.1155\/2019\/6032631FromNLMMedline","volume":"2019","author":"PC Chang","year":"2019","unstructured":"Chang PC, Lin SF, Chu Y, Wo HT, Lee HL, Huang YC, Wen MS, Chou CC. LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model. Cardiovasc Ther. 2019;2019:6032631. https:\/\/doi.org\/10.1155\/2019\/6032631FromNLMMedline.","journal-title":"Cardiovasc Ther"},{"issue":"11","key":"2157_CR218","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/jce.15670FromNLMMedline","volume":"33","author":"E Huang","year":"2022","unstructured":"Huang E, Bernard ML, Elise Hiltbold A, Khatib S, Polin GM, Rogers PA, Dominic P, Morin DP. Sacubitril\/valsartan: An antiarrhythmic drug? J Cardiovasc Electrophysiol. 2022;33(11):2375\u201381. https:\/\/doi.org\/10.1111\/jce.15670FromNLMMedline.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2157_CR219","doi-asserted-by":"publisher","unstructured":"Zhou Y, Rui S, Tang S, Ju C. Exploration of Mechanisms of Sacubitril\/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach. Front Cardiovascular Med 2022;9. https:\/\/doi.org\/10.3389\/fcvm.2022.829484.","DOI":"10.3389\/fcvm.2022.829484"},{"key":"2157_CR220","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-024-03619-1","author":"AM Kamsheh","year":"2024","unstructured":"Kamsheh AM, Bilker WB, Huang Y-S, Okunowo O, Burstein DS, Edelson JB, Lin KY, Maeda K, Mavroudis CD, O\u2019Connor MJ, et al. Prolonged Inotrope Use After Surgery for Congenital Heart Disease: A Common Occurrence with a High Burden of Mortality. Pediatr Cardiol. 2024. https:\/\/doi.org\/10.1007\/s00246-024-03619-1.","journal-title":"Pediatr Cardiol"},{"key":"2157_CR221","doi-asserted-by":"publisher","unstructured":"Vieillard-Baron A, Prigent A, Repess\u00e9 X, Goudelin M, Prat G, Evrard B, Charron C, Vignon P, Geri G. Right ventricular failure in septic shock: characterization, incidence and impact on fluid responsiveness. Critical Care 2020;24(1). https:\/\/doi.org\/10.1186\/s13054-020-03345-z.","DOI":"10.1186\/s13054-020-03345-z"},{"issue":"3","key":"2157_CR222","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.chest.2020.09.274FromNLMMedline","volume":"159","author":"MJ Lanspa","year":"2021","unstructured":"Lanspa MJ, Cirulis MM, Wiley BM, Olsen TD, Wilson EL, Beesley SJ, Brown SM, Hirshberg EL, Grissom CK. Right Ventricular Dysfunction in Early Sepsis and Septic Shock. Chest. 2021;159(3):1055\u201363. https:\/\/doi.org\/10.1016\/j.chest.2020.09.274FromNLMMedline.","journal-title":"Chest"},{"key":"2157_CR223","doi-asserted-by":"publisher","unstructured":"Campbell P, Takeuchi M, Bourgoun M, Shah A, Foster E, Brown MW, Goldenberg I, Huang DT, McNitt S, Hall WJ et al. Right Ventricular Function, Pulmonary Pressure Estimation, and Clinical Outcomes in Cardiac Resynchronization Therapy. Circulation: Heart Failure 2013;6 (3):435\u2013442. https:\/\/doi.org\/10.1161\/circheartfailure.112.000127.","DOI":"10.1161\/circheartfailure.112.000127"},{"issue":"8","key":"2157_CR224","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/j.1540-8159.2009.02436.x","volume":"32","author":"L Scuteri","year":"2009","unstructured":"Scuteri L, Rordorf R, Marsan NA, Landolina M, Magrini G, Klersy C, Frattini F, Petracci B, Vicentini A, Campana C, et al. Relevance of Echocardiographic Evaluation of Right Ventricular Function in Patients Undergoing Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2009;32(8):1040\u20139. https:\/\/doi.org\/10.1111\/j.1540-8159.2009.02436.x.","journal-title":"Pacing Clin Electrophysiol"},{"key":"2157_CR225","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.hjc.2023.03.002FromNLMMedline","volume":"73","author":"G Sidiropoulos","year":"2023","unstructured":"Sidiropoulos G, Antoniadis A, Saplaouras A, Bazoukis G, Letsas Kappa P, Karamitsos TD, Giannopoulos G, Fragakis N. Impact of baseline right ventricular function on the response to cardiac resynchronization therapy - A meta-analysis. Hellenic J Cardiol. 2023;73:61\u20138. https:\/\/doi.org\/10.1016\/j.hjc.2023.03.002FromNLMMedline.","journal-title":"Hellenic J Cardiol"},{"issue":"11","key":"2157_CR226","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/clc.22762","volume":"40","author":"A Sharma","year":"2017","unstructured":"Sharma A, Lavie CJ, Vallakati A, Garg A, Goel S, Lazar J, Fonarow GC. Changes in parameters of right ventricular function with cardiac resynchronization therapy. Clin Cardiol. 2017;40(11):1033\u201343. https:\/\/doi.org\/10.1002\/clc.22762.","journal-title":"Clin Cardiol"},{"issue":"3","key":"2157_CR227","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1161\/circulationaha.116.025290","volume":"136","author":"NK Kapur","year":"2017","unstructured":"Kapur NK, Esposito ML, Bader Y, Morine KJ, Kiernan MS, Pham DT, Burkhoff D. Mechanical Circulatory Support Devices for Acute Right Ventricular Failure. Circulation. 2017;136(3):314\u201326. https:\/\/doi.org\/10.1161\/circulationaha.116.025290.","journal-title":"Circulation"},{"key":"2157_CR228","doi-asserted-by":"publisher","unstructured":"Kuroda T, Miyagi C, Fukamachi K, Karimov JH. Mechanical circulatory support devices and treatment strategies for right heart failure. Front Cardiovascular Med 2022;9. https:\/\/doi.org\/10.3389\/fcvm.2022.951234.","DOI":"10.3389\/fcvm.2022.951234"},{"key":"2157_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2024.07.006","author":"AP Carnicelli","year":"2024","unstructured":"Carnicelli AP, Diepen SV, Gage A, Bernhardt AM, Cowger J, Houston BA, Siuba MT, Kataria R, Beavers CJ, John KJ, et al. Pragmatic approach to temporary mechanical circulatory support in acute right ventricular failure. J Heart Lung Transplant. 2024. https:\/\/doi.org\/10.1016\/j.healun.2024.07.006.","journal-title":"J Heart Lung Transplant"},{"issue":"8 Pt 1","key":"2157_CR230","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jchf.2023.04.014FromNLMMedline","volume":"11","author":"I Rajapreyar","year":"2023","unstructured":"Rajapreyar I, Soliman O, Brailovsky Y, Tedford RJ, Gibson G, Mohacsi P, Hajduczok AG, Tchantchaleishvili V, Wieselthaler G, Rame JE, et al. Late Right Heart Failure After Left Ventricular Assist Device Implantation: Contemporary Insights and Future Perspectives. JACC Heart Fail. 2023;11(8 Pt 1):865\u201378. https:\/\/doi.org\/10.1016\/j.jchf.2023.04.014FromNLMMedline.","journal-title":"JACC Heart Fail"},{"issue":"S1","key":"2157_CR231","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12055-023-01481-z","volume":"39","author":"C Siems","year":"2023","unstructured":"Siems C, Aggarwal R, Shaffer A, John R. Right heart failure after left ventricular assist device implantation: a persistent problem. Indian J Thoracic Cardiovascular Surgery. 2023;39(S1):161\u20139. https:\/\/doi.org\/10.1007\/s12055-023-01481-z.","journal-title":"Indian J Thoracic Cardiovascular Surgery"},{"key":"2157_CR232","doi-asserted-by":"publisher","unstructured":"Kuroda T, Miyagi C, Fukamachi K, Karimov JH. Biventricular assist devices and total artificial heart: Strategies and outcomes. Front Cardiovascular Med 2023;9. https:\/\/doi.org\/10.3389\/fcvm.2022.972132.","DOI":"10.3389\/fcvm.2022.972132"},{"issue":"2","key":"2157_CR233","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cjca.2019.11.027","volume":"36","author":"P-E Noly","year":"2020","unstructured":"Noly P-E, Ben Ali W, Lamarche Y, Carrier M. Status, Indications, and Use of Cardiac Replacement Therapy in the Era of Multimodal Mechanical Approaches to Circulatory Support: A Scoping Review. Can J Cardiol. 2020;36(2):261\u20139. https:\/\/doi.org\/10.1016\/j.cjca.2019.11.027.","journal-title":"Can J Cardiol"},{"issue":"5","key":"2157_CR234","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/aor.13959FromNLMMedline","volume":"45","author":"JJ Han","year":"2021","unstructured":"Han JJ. Aeson-The Carmat total artificial heart is approved for enrollment in the United States. Artif Organs. 2021;45(5):445\u20136. https:\/\/doi.org\/10.1111\/aor.13959FromNLMMedline.","journal-title":"Artif Organs"},{"key":"2157_CR235","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.xjon.2021.09.046","volume":"8","author":"E Potapov","year":"2021","unstructured":"Potapov E, Starck C, Falk V, Eulert-Grehn J-J. Mechanical circulatory support: Technical tips for the implantation of a right ventricular assist device. JTCVS Open. 2021;8:37\u201340. https:\/\/doi.org\/10.1016\/j.xjon.2021.09.046.","journal-title":"JTCVS Open"},{"key":"2157_CR236","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.xjon.2020.06.006","volume":"3","author":"T Miyamoto","year":"2020","unstructured":"Miyamoto T, Kado Y, Horvath DJ, Kuban BD, Sale S, Fukamachi K, Karimov JH. An advanced universal circulatory assist device for left and right ventricular support: First report of an acute in vivo implant. JTCVS Open. 2020;3:140\u20138. https:\/\/doi.org\/10.1016\/j.xjon.2020.06.006.","journal-title":"JTCVS Open"},{"key":"2157_CR237","doi-asserted-by":"crossref","unstructured":"Riccardi M, Tomasoni D, Vizzardi E, Metra M, Adamo M. Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction. Heart Failure Reviews. 2022;10280\u20134","DOI":"10.1007\/s10741-022-10280-4"},{"key":"2157_CR238","doi-asserted-by":"publisher","first-page":"101203","DOI":"10.1016\/j.jscai.2023.101203","volume":"2","author":"V Jagadeesan","year":"2023","unstructured":"Jagadeesan V, Gray WA, Shah SJ. Atrial Shunt Therapy for Heart Failure: An Update. J Soc Cardiovascular Angiography Interventions. 2023;2:101203.","journal-title":"J Soc Cardiovascular Angiography Interventions"},{"key":"2157_CR239","doi-asserted-by":"publisher","first-page":"706","DOI":"10.4244\/EIJY15M07_08","volume":"11","author":"MB Patel","year":"2015","unstructured":"Patel MB, Samuel BP, Girgis RE, Parlmer MA, Vettukattil JJ. Implantable atrial flow regulator for severe, irreversible pulmonary arterial hypertension. EuroIntervention. 2015;11:706\u20139.","journal-title":"EuroIntervention"},{"key":"2157_CR240","doi-asserted-by":"crossref","unstructured":"Pattathu J, Michel S, Tengler A, et al. Case report: Beneficial long-term effect of the atrial-flow-regulator device in a pediatric patient with idiopathic pulmonary arterial hypertension and recurring syncope. Frontiers in Cardiovascular Medicine. 2023;1197985","DOI":"10.3389\/fcvm.2023.1197985"},{"key":"2157_CR241","doi-asserted-by":"publisher","first-page":"1073336","DOI":"10.3389\/fped.2023.1073336","volume":"11","author":"DE Youssef","year":"2023","unstructured":"Youssef DE, Averin K, Richards S, et al. North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients. Front Pediatr. 2023;11:1073336.","journal-title":"Front Pediatr"},{"key":"2157_CR242","doi-asserted-by":"publisher","first-page":"1332395","DOI":"10.3389\/fcvm.2023.1332395","volume":"10","author":"G Butera","year":"2024","unstructured":"Butera G, Piccinelli E, Kolesnik A, et al. Implantation of atrial flow regulator devices in patients with congenital heart disease and children with severe pulmonary hypertension or cardiomyopathy\u2014an international multicenter case series. Front Cardiovascular Med. 2024;10:1332395.","journal-title":"Front Cardiovascular Med"},{"key":"2157_CR243","doi-asserted-by":"publisher","first-page":"107","DOI":"10.32604\/CHD.2022.018590","volume":"17","author":"B O\u2019Callaghan","year":"2022","unstructured":"O\u2019Callaghan B, Zablah J, Vettukattil J, et al. Multi-Institutional US Experience of the Occlutech-AFR Device in Congenital and Acquired Heart Disease. Congenit Heart Dis. 2022;17:107\u201316.","journal-title":"Congenit Heart Dis"},{"key":"2157_CR244","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/fca-2019-0044","volume":"16","author":"CM Campbell","year":"2020","unstructured":"Campbell CM, Kahwash R, Abraham WT. Optimizer Smart in the Treatment of moderate-to-severe Chronic Heart Failure. Future Cardiol. 2020;16:13\u201325.","journal-title":"Future Cardiol"},{"key":"2157_CR245","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.3390\/app12157917","volume":"12","author":"C Contaldi","year":"2022","unstructured":"Contaldi C, De Vivo S, Martucci ML, et al. Effects of Cardiac Contractility Modulation Therapy on Right Ventricular Function: An Echocardiographic Study. Appl Sci. 2022;12:7917.","journal-title":"Appl Sci"},{"key":"2157_CR246","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1016\/j.jacc.2005.05.093","volume":"46","author":"T Lawo","year":"2005","unstructured":"Lawo T, Borggrefe M, Butter C, et al. Electrical Signals Applied During the Absolute Refractory Period. JACC. 2005;46:2229\u201336.","journal-title":"JACC"},{"key":"2157_CR247","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jacc.2008.01.036","volume":"51","author":"C Butter","year":"2008","unstructured":"Butter C, Rastogi S, Minden H-H, et al. Cardiac Contractility Modulation Electrical Signals Improve Myocardial Gene Expression in Patients With Heart Failure. JACC. 2008;51:1784\u20139.","journal-title":"JACC"},{"key":"2157_CR248","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000445624","volume":"39","author":"F Zhang","year":"2016","unstructured":"Zhang F, Dang Y, Li Y, et al. Cardiac Contractility Modulation Attenuate Myocardial Fibrosis by Inhibiting TGF-\u03b21\/Smad3 Signaling Pathway in a Rabbit Model of Chronic Heart Failure. Cell Physiol Biochem. 2016;39:294\u2013302.","journal-title":"Cell Physiol Biochem"},{"key":"2157_CR249","first-page":"413","volume":"34","author":"JR Klinger","year":"2016","unstructured":"Klinger JR. Group III pulmonary hypertension: pulmonary hypertension associated with lung disease\u2014epidemiology, pathophysiology, and treatments. Cardiol Clin. 2016;34:413\u201333.","journal-title":"Cardiol Clin"},{"key":"2157_CR250","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1161\/CIRCULATIONAHA.106.685206","volume":"116","author":"MK Han","year":"2007","unstructured":"Han MK, McLaughlin VV, Criner GJ, et al. Pulmonary diseases and the heart. Circulation. 2007;116:2992\u20133005.","journal-title":"Circulation"},{"key":"2157_CR251","doi-asserted-by":"publisher","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","volume":"53","author":"SD Nathan","year":"2019","unstructured":"Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53:1801914.","journal-title":"Eur Respir J"},{"key":"2157_CR252","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1165\/ajrcmb.16.2.9032126","volume":"16","author":"D Saleh","year":"1997","unstructured":"Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol. 1997;16:187\u201393.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2157_CR253","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijcard.2018.09.043","volume":"273","author":"JY Cao","year":"2018","unstructured":"Cao JY, Wales KM, Cordina R, Lau EMT, Celermajer DS. Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: A meta-analysis. Int J Cardiol. 2018;273:213\u201320.","journal-title":"Int J Cardiol"},{"key":"2157_CR254","doi-asserted-by":"crossref","unstructured":"Arif R, Pandey A, Zhao Y,et al.Treatment of pulmonary hypertension associated with COPD: a systematicreview.ERJ Open Res2022; 8: 00348\u20132021","DOI":"10.1183\/23120541.00348-2021"},{"key":"2157_CR255","doi-asserted-by":"publisher","unstructured":"Shlobin OA, Adir Y, Barbera JA et al. Pulmonary hypertension associated with lung diseases. European Respiratory Journal. 2024: 2401200. https:\/\/doi.org\/10.1183\/13993003.01200-2024","DOI":"10.1183\/13993003.01200-2024"},{"key":"2157_CR256","doi-asserted-by":"publisher","first-page":"220116","DOI":"10.1183\/16000617.0116-2022","volume":"32","author":"GM Verleden","year":"2023","unstructured":"Verleden GM, Gottlieb J. Lung transplantation for COPD\/pulmonary emphysema. Eur Respir Rev. 2023;32:220116. https:\/\/doi.org\/10.1183\/16000617.0116-2022.","journal-title":"Eur Respir Rev"},{"key":"2157_CR257","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894018776518","volume":"8","author":"A Bauer","year":"2018","unstructured":"Bauer A, Khalil M, Schmidt D, et al. Creation of a restrictive atrial communication in pulmonary arterial hypertension (PAH): effective palliation of syncope and end-stage heart failure. Pulmonary Circulation. 2018;8:1\u20139. https:\/\/doi.org\/10.1177\/2045894018776518.","journal-title":"Pulmonary Circulation"},{"key":"2157_CR258","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.ccm.2013.09.002","volume":"34","author":"SG Norfolk","year":"2013","unstructured":"Norfolk SG, Lederer DJ, Tapson VF. Lung transplantation and atrial septostomy in pulmonary arterial hypertension. Clin Chest Med. 2013;34:857\u201365.","journal-title":"Clin Chest Med"},{"issue":"6","key":"2157_CR259","doi-asserted-by":"publisher","first-page":"e090522204486","DOI":"10.2174\/1573403X18666220509203335","volume":"18","author":"B Mendel","year":"2022","unstructured":"Mendel B, Christianto C, Angellia P, Holiyono I, Prakoso R, Siagian SN. Reversed Potts Shunt Outcome in Suprasystemic Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Curr Cardiol Rev. 2022;18(6):e090522204486. https:\/\/doi.org\/10.2174\/1573403X18666220509203335.","journal-title":"Curr Cardiol Rev"},{"key":"2157_CR260","doi-asserted-by":"publisher","first-page":"52","DOI":"10.5090\/kjtcs.2015.48.1.52","volume":"48","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jang WS, Lim HG, Kim YJ. Potts shunt in patients with primary pulmonary hypertension. Korean J Thorac Cardiovasc Surg. 2015;48:52\u20134.","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"2157_CR261","doi-asserted-by":"crossref","unstructured":"Leard LE, Holm AM, Valapour M,et al. Consensus document for the selection of lung transplant candidates:an update from the International Society for Heart and Lung Transplantation.J Heart Lung Transplant. 2021;40: 1349\u20131379","DOI":"10.1016\/j.healun.2021.07.005"},{"key":"2157_CR262","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.healun.2017.07.016","volume":"36","author":"DC Chambers","year":"2017","unstructured":"Chambers DC, Yusen RD, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time. J Heart Lung Transplant. 2017;36:1047\u201359.","journal-title":"J Heart Lung Transplant"},{"key":"2157_CR263","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/icvts\/ivt111","volume":"17","author":"A Olland","year":"2013","unstructured":"Olland A, Falcoz PE, Canuet M, et al. Should we perform bilateral-lung or heart\u2013lung transplantation for patients with pulmonary hypertension? Interact Cardiovasc Thorac Surg. 2013;17:166\u201370.","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2157_CR264","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.healun.2021.07.021","volume":"40","author":"D Chambers","year":"2021","unstructured":"Chambers D, Perch M, Zuckermann A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult lung transplantation report \u2013 2021; focus on recipient characteristics. J Heart Lung Transplant. 2021;40:1060\u201372. https:\/\/doi.org\/10.1016\/j.healun.2021.07.021.","journal-title":"J Heart Lung Transplant"},{"key":"2157_CR265","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.healun.2016.09.001","volume":"35","author":"RD Yusen","year":"2016","unstructured":"Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016;35:1170\u201384.","journal-title":"J Heart Lung Transplant"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02157-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-024-02157-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02157-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:55:51Z","timestamp":1772096151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-024-02157-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":265,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2157"],"URL":"https:\/\/doi.org\/10.1007\/s11886-024-02157-9","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"22 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable, as this is a review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Yes, approved by the author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}],"article-number":"26"}}